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 High throughput screening (HTS) has emerged as a reliable 
component of the drug discovery process. It is now recognized that a large number of 
compounds inhibit their target enzyme via an aggregation-based binding mechanism 
leading to false positive results in HTS assays. Aggregate-forming compounds act 
non-competitively; show little relation between structure and activity; have steep 
dose-response curves and are reported to inhibit multiple unrelated enzymes 
(McGovern et al. 2002; McGovern et al. 2003; Feng et al. 2007).  Removal of these 
compounds from screening hit lists is desirable as they are not good starting points to 
initiate medicinal chemistry programs. There are many techniques currently in use to 
identify aggregation-based inhibition such as dynamic light scattering (DLS), testing 
sensitivity of inhibition potency to detergent or enzyme concentration, and 
measurement of meniscus curvature changes in high density multi-well plates 
associated with colloidal changes in solution.  
To evaluate the feasibility of large-scale identification of aggregate-based 
inhibition, hits from three enzyme screens (β-Lactamase, DENV RdRp and 
Pantothenate kinase) were analysed for signs of aggregate-based inhibitions using 
various techniques. For a majority of non-specific hits, characteristic features of 
aggregate-based inhibition such as steep dose-response curves, presence of aggregate 
particles in solution and inhibition of unrelated enzymatic targets were not found to 
be associated with detergent or enzyme-concentration sensitive inhibition. Particle 
size measurements by DLS were inconsistent for many compounds. Steepness of 




Aggregate-based inhibitors displayed target specificity towards their respective target 
enzymes rather than ‘promiscuous’ inhibition of multiple targets.  
Different detergents often yielded conflicting results and required derivation 
of new cut-offs for different enzyme systems or different assay conditions. For 
example, while the sensitivity of inhibition potency to detergent was not dependent 
on the nature of the detergent for hits of β-Lactamase, this was not the case for hits of 
the DENV RdRp enzyme. The inhibition potencies of the hits of DENV RdRp were 
found to have different degrees of sensitivity to different detergents. Furthermore, the 
results of the enzyme-concentration sensitivity tests for the DENV RdRp hits did not 
seem to correlate with the detergent-sensitivity results. It was observed that the 
interaction between the enzyme and its substrate possibly confounded the effect of 
varying the enzyme concentration.  
The measurement of changes in meniscus curvature, as a means of 
identification of aggregate-forming small molecule compounds, has been used for the 
first time in an actual HTS campaign, as reported in this study. The meniscus 
measurements of hits from all screens correlated well with detection of aggregation-
based inhibition based on measurement of changes in inhibition potency. A 
classiﬁcation scheme is presented that can be used to rapidly characterize the hits 
from high throughput screens and eliminate compounds with a non-speciﬁc 
mechanism of inhibition. In summary, the meniscus-based aggregation assay is 
simple, cost-effective, and a reliable method to identify and eliminate compounds that 
inhibit a specific target enzyme via an aggregation-based mechanism. 
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1.1 Introduction to High Throughput Screening 
High throughput screening (HTS) is a widely used approach to discover 
novel chemical entities for drug design. In concert with the generation of large 
libraries of chemically diverse small molecules, the advancements in automation 
technologies have lead to growth of HTS programs in academia and industry (Inglese 
et al. 2007; Shelat and Guy 2007). A recent worldwide study involving 58 HTS 
laboratories has reported increasing numbers of leads identified by HTS over the 
years (Fig. 1) and documented 104 clinical candidates and four marketed products 
that have emerged from these leads (Fox et al. 2006).   
 
Figure 1: Historical comparison of number of leads found by HTS study 
participants. Reprinted with permission from “High-throughput screening: 
update on practices and success” by Fox et al in J Biomol Screen, 2006 
11(7):864-869. Copyright 2006 by Sage Publications.  
 
HTS methodology enables expeditious screening of sizeable chemical 
libraries to identify leads that act on a biological target of interest, e.g., as inhibitors 
of target enzymes, as competitors for binding of a natural ligand to its receptor, as 
agonists or antagonists of receptor-mediated intracellular processes, and so forth.  
HTS assays involve a variety of strategies such as the measurement of catalytic 
activity from a purified enzyme (Zhang et al. 1999), a reconstituted complex of a 
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signalling pathway (McDonald et al. 1999), a cellular extract (Verma et al. 2004), or 
measurement of phenotypic changes (Hodder et al. 2004) in intact cells. Configuring 
assays to function within the constraints imposed by high-throughput settings 
differentiates an HTS assay from traditional laboratory assays, as outlined in Table 1. 
Table 1: Differences in allowed parameters between laboratory “bench top” and 
HTS assays. Reprinted with permission from “High-throughput screening assays 
for the identification of chemical probes” by Inglese et al.  in Nat Chem Biol 
2007;3(8):466-479. Copyright  2007 by Macmillan Publishers Ltd.  
Parameter Bench top HTS 
Protocol May be complex with 
numerous steps, 
aspirations, washes 
Few (5–10) steps, simple 
operations, addition only 
preferred 
Assay volume 0.1 ml to 1 ml <1 µl to 100 µl 
Reagents Quantity often limited, 
batch variation acceptable, 
may be unstable 
Sufficient quantity, single 
batch, must be stable over 
prolonged period 
Reagent handling Manual Robotic 
Variables Many-for example, time, 
substrate/ligand 




Assay container Varied-tube, slide, 
microtiter plate, Petri dish, 
cuvette, animal 
Microtiter plate 
Time of measurement Milliseconds to months. 
Measurements as endpoint, 
multiple time points, or 
continuous 
Minutes to hours. 
Measurements typically 
endpoint, but also pre-read 
and kinetic 
Output formats Plate reader, radioactivity, 
size separation, object 
enumeration,  images 






Reporting format  “Representative” data; 
statistical analysis of 
manually curated dataset 
Automated analysis of all 





1.2 Steps involved in setting up a high throughput screen 
1.2.1 Assessment of assay quality 
Large screens involving hundreds of thousands of compounds are expensive 
in time and resources. Thus before starting a large screen, it is important to assess the 
suitability or quality of the assay to be used in screening and ascertain if the assay 
would be useful in a high-throughput setting. A statistical term, called the Z or Z’-
factor (Zhang et al. 1999), is commonly used to evaluate the quality of assays.  
 
 
The Z or Z’-factor is defined in terms of four parameters: the means and 
standard deviations of both the positive (p) and negative (n) controls (µp, σp, and µn, 
σn).  A Z-factor of 1 is considered ideal.  This value is approached when there is a 
huge dynamic range (large difference between the signal means of the positive and 
negative controls) with small standard deviations. Z-factors can never be greater than 
1.  A value between 0.5 and 1 is aspired for in HTS settings. A Z-factor between 0 
and 0.5 is considered sub-optimal. If an assay has a Z-factor that is less than 0, it 
implies that the signals from the positive and negative controls could overlap, making 
the assay essentially useless for screening purposes. 
1.2.2 Primary screen 
The goal of any HTS campaign is to identify active compounds (“hits”) and 
choose the best candidates for lead optimization. This is achieved through a multitude 
of steps (Fig. 2). After an assay has been developed and validated, entire chemical 
libraries (hundreds of thousands to millions of compounds) are screened against the 
target of interest. Primary screening usually involves single measurements of the 
activity of each small-molecule compound. These single data points of unknown 
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samples are compared to positive and negative control samples to determine which 
compounds are active against the biological target. A robust assay with a Z-factor 
between 0.5 and 1 is conducive to single point testing. An assay with a sub-optimal 
Z-factor between 0 and 0.5 would require multiple data points for each compound to 
ensure reproducibility of the assay readout. 
 
 
Figure 2: Illustration of steps involved in the initial drug discovery process 
 
1.3 Hit to lead phase 
The hit rate from a primary screen can vary between 0.1 and 1% (Eisenthal 
and Danson 2002) depending on the target, the assay format and the cut-off used to 
decide if a compound is considered ‘active’ or not. After selecting hits from 
compounds tested in the primary screen, the next step is to confirm the activity of 
these hits. Establishing a dose-response relationship is an important step in hit 
confirmation. It routinely involves a secondary screen in which a range of compound 
concentrations usually prepared by serial dilution are tested in an assay to assess the 
concentration or dose dependence of the assay's readout. Typically, this dose-
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response is expressed as the 50% inhibitory concentration (IC50) in enzyme-, protein-, 
antibody-based assays; or as the half maximal effective concentration (EC50) in cell-
based experiments. Compounds that display potency in a dose-dependent manner are 
chosen for further analysis. 
1.3.1 Selectivity 
Lead candidates should ideally interfere with only the chosen target, and not 
other, related targets. Selectivity toward a drug target decreases the risk of off-target 
toxicity that might occur in the clinical trial stage. Screens for selectivity usually 
include drug targets of the same protein or receptor family, for example, panels of G 
protein-coupled receptors (Swanson and Beasley 2010) or kinases (Fabian et al. 2005; 
Goldstein et al. 2008; Karaman et al. 2008). In cases where selectivity between 
subtypes is important, screens might include a panel of homologous enzymes, 
different protein complexes, or heterooligomers. Selectivity screens enable profiling 
of the action of a confirmed hit on a defined spectrum of biological target classes. 
Ideally, only those compounds which are highly selective towards the target of 
interest will progress to the next stage.  
1.3.2 Evaluation of potential lead candidates 
It has been studied that more often than not, marketed drugs are similar to the 
leads from which they originate (Proudfoot 2002). Therefore it is of utmost 
importance to choose the best hits to promote to lead status. The most desirable 
binding characteristics a ‘lead’ like compound should have are: non-covalent, high 
affinity ligand binding; reversible, competitive binding; and tractability in structure–
activity relationship (SAR) of a series of structural analogues of the binder (Rishton 
2003). Furthermore, it has been well established that potency alone is a false predictor 
of ‘lead’ likeness (Wunberg et al. 2006) and that an ideal lead molecule must exhibit 
a balance of potency, selectivity, and favourable physicochemical properties.  
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 Therefore, merely re-confirming target inhibition is an inadequate measure of 
the quality of a hit as it doesn’t necessarily ensure that the compound satisfies the 
required criteria. Many compounds can appear to possess ‘lead’ like characteristics in 
a HTS assay. However, false positives can result from multiple mechanisms, 
including: non-specific hydrophobic binding, poor solubility (protein or substrate 
precipitation), reactive functional groups, low purity, assay interference, aggregation-
based enzyme inhibition and experimental errors (Keseru and Makara 2006). Some 
concerns, such as false positivity due to reactive functional groups, can be addressed 
by triaging of hit lists by medicinal chemists and elimination of compounds with 
undesirable chemical structures (Rishton 1997).  
Other concerns such as assay interference require more intensive probing. 
Therefore hits are subjected to a battery of follow-up assays or counter screens to 
identify those that don’t exhibit the intended biological interaction or falsely appear 
active due to confounding factors.  The number and stringency of counter screens can 
vary widely and depend on the drug target.  The next section provides an overview of 
some of the ways a compound can appear active in a biochemical assay without 
possessing any biological activity and strategies to identify these false positives. 
 
1.4 Sources of false positives in high throughput screening 
1.4.1 Interference in assay readout 
Current HTS technologies are largely based on sensitive light based detection 
methods, such as ﬂuorescence or luminescence, to quantify the effect of a compound 
on a target enzyme, receptor or signalling pathway (Inglese et al. 2007). These assay 
types are preferred because of their high sensitivity, flexibility across multiple 
homogeneous formats, ease of miniaturization, and applicability across a wide range 
of targets. However, they are highly sensitive to spectral artifacts (Shapiro et al. 
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2009). For instance, false negatives can occur due to light scattering, coloured, or 
fluorescent compounds that contribute to the net fluorescence signal. Small-molecule 
compounds are able to interfere with the fluorometric readout in many cases. The 
most straightforward interference results from spectral overlap between screening 
compounds and the assay system in optical and fluorescence assay formats (Gribbon 
and Sewing 2003). Compounds may falsely be identified as inhibitors if they absorb 
light at the detection wavelength of the fluorogenic substrate. In such cases, the net 
fluorescence signal measured in the assay will be attenuated by the compound to be 
tested. As a result, a reduction of the fluorescence signal is detected even in the 
absence of any interaction of the compound with the enzyme (Liu et al. 1999; Birdsall 
et al. 1983).  
A recent study profiling the fluorescence spectral properties (Simeonov et al. 
2008) of about 70,000 compounds (PubChem Assay IDs – 587-594,709) found that 
2–5% of the compounds in the library fluoresced in the blue spectral region (~350-
500 nm) and that for several fluorescence-based assays involving excitation in the 
blue spectral region, up to 50% of the hits identified in the screen were actually 
fluorescently active. The study further reported that when excited at red-shifted 
wavelengths (~600 nm); only 0.004–0.01% of the library fluoresced, indicating that 
use of red-shifted fluorophores is one way to reduce this mode of generation of false 
positives. Other methods to counter spectral interference are: inclusion of  a pre-read 
after compound addition but prior to fluorophore addition to the reaction; inclusion of 
a time delay after excitation of fluorophore (time-resolved); use of a ratiometric 






1.4.2 Inhibition of detection system 
Assay set-ups that employ enzyme-coupling systems are another example of 
a complex system that may suffer from detection interference. Many enzymes form 
reaction products that are not amenable to direct detection in an in vitro biochemical 
assay. To obtain a convenient spectral readout, the target enzyme’s activity may be 
monitored by coupling its product to the reaction of an additional enzyme or auxiliary 
enzymes. The coupling reaction utilizes the target enzyme reaction product to 
produce a colorimetric (e.g., lactate dehydrogenase-coupled NADPH oxidation to 
detect pyruvate formation) or fluorescent (e.g., horseradish peroxidase-coupled 
fluorescent dye oxidation to detect H2O2 formation) or luminescent (e.g., luciferase-
coupled detection of ATP production by kinases) signal. However, the coupled 
enzyme itself may be susceptible to inhibition by small molecules. For example, a 
proﬁling effort of a 70,000 compound library (PubChem Assay ID - 411) determined 
that at least 3% of the library inhibited firefly luciferase activity in a concentration 
dependent manner (Auld et al. 2008) demonstrating that HTS hit lists may contain a 
large number of compounds that inhibit the coupled enzyme rather than the target 
enzyme. 
Direct assays can be carried out to test if apparent compound activity is due 
to inhibition of the coupling enzyme. Inhibitors of the coupling system can also be 
eliminated by counter screening hits using the same coupling system, but with a 
different target enzyme that produces the same reaction product as the original target 
enzyme (Seethala and Zhang 2009). If the other enzyme is related to the original 
target enzyme or from the same family, selectivity considerations can be addressed at 
the same time. Any compound that is positive in this counter screen may then be 
eliminated from consideration regardless of whether it inhibits the coupling enzyme 
or the undesired counter screening enzyme. Another method to distinguish between 
assay format-dependent inhibition and target-specific inhibition is to re-test the 
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activity of hits in an orthogonal assay, i.e. an assay that has a different readout 
compared to the format used in the original screening methodology (e.g., use of 
fluorescence readout as opposed to absorbance). 
1.4.3 Aggregation-based enzymatic inhibition in biochemical assays 
Compound aggregation, through self association of organic molecules in 
aqueous media, was recently discovered to be one of the main causes for false 
positives in HTS (McGovern et al. 2002).  The study by Brian Shoichet’s group 
reported that above a certain concentration some small-molecule compounds self-
associate to form aggregate particles. These particles, at 30–400 nm in size, strongly 
scattered light detectable by dynamic light scattering and could be visualized by 




Figure 3: Aggregating compounds visualized by transmission electron 
microscopy (McGovern et al. 2002). A to C- 100 µM tetraiodophenolphthalein in 
20 mM Tris; D- 50 µM Congo Red in 20 mM Tris; E- 625 µM ANS in 20 mM 
Tris. Bar = 100 nm. ANS – negative control. Reprinted with permission from “A 
common mechanism underlying promiscuous inhibitors from virtual and high-
throughput screening” by McGovern et al. in J Med Chem 2002;45(8):1712-
1722. Copyright  2002 by American Chemical Society.  
 These ‘aggregators’ that were initially identified as inhibitors of enzyme 
targets such as dihydrofolate reductase, thymidylate synthase, insulin receptor, 
tyrosine kinases, etc; were also found to inhibit several unrelated model enzymes 
such as β-Lactamase, β-Galactosidase and chymotrypsin. Decreased inhibition in the 
presence of bovine serum albumin suggested a non-specific mechanism of action and 
implied that inhibition by these molecules could be attenuated in the presence of 
excess protein. The compounds also showed sensitivity to the molar ratio of inhibitor 
to enzyme. Increasing the concentration of the model enzymes by 10-fold 
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significantly decreased the inhibition potency (increased the IC50) of these 
‘aggregators’ but not of classical, well-behaved inhibitors. To investigate if an 
aggregate-based inhibition model could explain the lack of specificity of many kinase 
inhibitors; 15 widely used known kinase inhibitors were analyzed for traits of non-
specific behaviour (McGovern and Shoichet 2003). It was found that more than half 
of the kinase inhibitors also inhibited unrelated model enzymes, displayed sensitivity 
to enzyme concentration and formed aggregates of 100-1000 nm diameter as 
observed by dynamic light scattering. Due to their propensity to inhibit a panel of 
unrelated enzymes, inhibitors that act via an aggregation-based inhibition are often 
called ‘promiscuous’ inhibitors. 
On the basis of the pilot studies, it was proposed that aggregate-forming 
compounds may be common in pharmaceutical screening libraries; and that such non-
specific inhibitors could artificially inflate hit rates in screening for new drug leads. 
Since these compounds act non-competitively, show little relation between structure 
and activity (flat SAR), and have poor specificity, their elimination from hit lists 
could potentially save a great deal of effort that would otherwise be spent in trying to 
optimize their apparent activity (Borchardt et al. 2004).  Therefore, Shoichet et al. 
have studied these aggregate-forming inhibitors in great detail and provided a better 
understanding of how they work; how frequently they occur in screening libraries; 
and techniques that can be used to detect aggregate-based inhibition; as described 
below in this section. 
In an effort to understand the mechanism of aggregation-based inhibition, 
Shoichet’s group studied the interaction of aggregate-forming inhibitors with model 
proteins like β-Lactamase. By using centrifugation and gel electrophoresis-based 
approaches, it was found that inhibition occurred via the direct binding of enzyme to 
aggregate (McGovern et al. 2003). β-Lactamase mutants with increased or decreased 
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thermodynamic stability relative to wild-type enzyme were equally inhibited by 
aggregate-forming compounds, suggesting that denaturation by unfolding was not the 
primary mechanism of action of aggregate-forming inhibitors. However, visualization 
by electron microscopy revealed that enzyme did associate with the surface of 
aggregated molecules. Interestingly, β-Lactamase inhibition by compound 
aggregation was found to be reversible by non-ionic detergents such as Triton X-100 
(McGovern et al. 2003; Ryan et al. 2003). Since the enzyme was thought to be 
sequestered by the aggregated compounds, it was inferred that the presence of 
detergents either prevented formation of aggregates or interfered in the binding of 
enzymes by aggregated compounds. 
Recently, the stoichiometry of binding of enzyme to aggregates was 
elucidated to be as high as 10,000 enzyme molecules per aggregate particle (Coan 
and Shoichet 2008). Given the size of the aggregates and the stoichiometry of 
binding, the aggregation model suggests that all sequestered enzyme can be 
accommodated on the surface on the aggregate (Fig. 4).  This deviation from the 
classical 1:1 enzyme to inhibitor stoichiometry also explains another phenomenon 
generally associated with aggregate forming inhibitors, namely steep dose-response 
curves (Shoichet 2006;Feng et al. 2007). In the case of a classical, single-site 
inhibitor, inhibition usually increases from 10% to 90% over a large (81-fold) 
concentration range, whereas for compounds displaying steep dose-response curves 
the same increase in inhibition is observed within a 10-fold range of compound 
concentration. Since aggregate-forming inhibitors are known to form aggregates only 
above a certain concentration, usually in the micromolar range (Coan and Shoichet 
2008), many aggregate-forming compounds are found to have steep dose-response 
curves with high Hill coefficients. 
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Shoichet and co-workers recently suggested that partial unfolding of the 
protein occurs upon aggregate binding (Coan et al. 2009).  They examined changes in 
solvent accessibility of the β-Lactamase enzyme upon binding to an aggregate-
forming inhibitor using hydrogen-deuterium mass spectrometry and noted that 
binding to aggregate particles increased deuterium exchange by the enzyme. This 
global increase in proton accessibility upon aggregate binding suggested a model 
consistent with partial denaturation of the protein (Fig. 4). This mechanism was 
confirmed by the observation that enzyme-aggregate complexes were more 
susceptible to tryptic proteolysis compared to free enzyme molecules. 
 
Figure 4: (A) Model of aggregate and enzyme binding. Reprinted with 
permission from “Stoichiometry and physical chemistry of promiscuous 
aggregate-based inhibitors” by Coan and Shoichet in J Am Chem Soc 
2008;130(29):9606-9612. Copyright 2008 by American Chemical Society. (B) 
Mechanism of action of small-molecule aggregators – binding to the aggregate 
promotes a partial unfolding event. Reprinted with permission from 
“Promiscuous aggregate-based inhibitors promote enzyme unfolding” by Coan 
et al.  in J Med Chem 2009;52(7):2067-2075. Copyright  2009 by American 
Chemical Society.  
Subsequent to the initial studies on aggregate-forming inhibitors of β-
Lactamase, aggregate-forming false positives have been discovered among inhibitors 
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of kinesin motor proteins (Reddie et al. 2006), phospho-
mannomutase/phosphoglucomutase (Liu et al. 2004), and reverse transcriptase 
(Frenkel et al. 2005); establishing the incidence of this spurious mode of inhibition 
among inhibitors of various enzymes.  
In an effort to estimate the prevalence of detergent-sensitive inhibition for a 
typical HTS involving a biochemical assay, investigators have tested various small-
molecule libraries for enzyme inhibition sensitive to Triton X-100 using β-Lactamase 
as a model enzyme. In a 96-well format assay, it was found that 19% of the 1030 
‘drug-like’ compounds tested demonstrated detergent-dependent inhibition when 
screened against β-Lactamase at 30 µM (Feng et al. 2005). For a library of ~ 70,000 
compounds (PubChem Assay Ids- 584, 585), screened in a 1536-well assay format,  
95% of the actives identified in the screen against β-Lactamase were Triton X-100 
sensitive (Feng et al. 2007; Babaoglu et al. 2008). A screen of  200,000 compounds 
against the cysteine protease cruzain (PubChem Assay ID- 2249) revealed that 
approximately 1.9% of the library  or 90% of the actives were detergent-sensitive 
inhibitors (Jadhav et al. 2010), indicating that the prevalence of this type of assay 
interference is neither library-specific nor limited to a particular type of enzyme, as 
cruzain and β-Lactamase are structurally and functionally different. Another study on 
cruzain inhibitors reported divergent modes of inhibition (competitive or aggregation-
based) dependent on assay conditions, within a homologous structure-activity series,  
demonstrating that aggregate-based inhibition could be responsible for multiple logs 
of apparent(interpretable) SAR (Ferreira et al. 2009).  
Recent studies have provided evidence that small-molecule aggregation 
exists in more biological contexts and is not just an artifact of in vitro high throughput 
biochemical assays. A study investigating the behaviour of aggregates in high protein 
concentrations found that aggregates appear to be more stable in ‘in vivo’ like 
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conditions where serum protein is present in abundance (Coan and Shoichet 2007).  
Another study illustrating the ability of chemical aggregators to block amyloid fiber 
formation by yeast prion proteins and prevent infection of yeast cells by Sup35 prions 
(Feng et al. 2008) also points to the fact that aggregates have potentially widespread 
effects in biological systems of varying complexity.    
Given the fact that many drug-like molecules and some known drugs (Seidler 
et al. 2003) are capable of forming colloidal aggregates there has been speculation 
that aggregation may affect the bioavailability of drugs within the body.  To address 
this concern, researchers tested Biopharmaceutics Classification System (BCS) class 
II and class IV drugs for aggregate formation in a buffer mimicking conditions in the 
small intestine (Doak et al. 2010). It was found that six of these drugs formed colloids 
at concentrations equal to or lower than the concentrations reached in the gut, 
suggesting that aggregation may have an effect on the absorption and in vivo 
distribution of these drugs. 
In a nutshell, screening hit lists appear to be inundated by aggregate-forming 
inhibitors. These hits are deceptive as the inhibition is reproducible (i.e., these 
compounds will consistently inhibit the target under the same experimental 
conditions) and dose-dependent. However, their mode of activity is undesirable; and 
the lack of sensitivity of their biological activity to structural changes (flat SAR) 
makes them poor starting points for medicinal chemistry.  
1.4.3.1 Detection of aggregation-based inhibition  
 
This section provides an overview of the different methods currently is use 
for detection of aggregation-based inhibition; and their advantages and limitations. 
Some methods of aggregation detection rely on characteristics of aggregate-based 
inhibition such as steep dose-response curves; sensitivity to detergent, enzyme 
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concentration or presence of bovine serum albumin (BSA). While many aggregate-
forming inhibitors have steep dose-response curves (Feng et al. 2007); this 
phenomenon is not exclusive to aggregate-forming inhibitors and could simply be a 
sign of potent inhibition (Straus et al. 1943; Shoichet 2006). Addition of BSA to the 
assay buffer is practicable in most cases, but BSA has binding sites for various drug 
classes and should be used with care as it can interfere with the binding of the 
compound to the target enzyme by sequestering small drug-like molecules (Bi et al. 
2009). 
It has been established that addition of 0.01-0.1% Triton X-100 to the assay 
reagents leads to significant attenuation of aggregate-based inhibition (McGovern et 
al. 2003; Feng et al. 2005; Feng et al. 2007). The most rapid method for identifying 
aggregate-based inhibitors is therefore to repeat screening in the presence of a 
detergent such as Triton X-100 and check for loss of potency. However, high 
amounts of detergent can have a deleterious effect on enzymatic activity (Manandhar 
et al. 2007; Nishiya et al. 1998) or influence reporter enzymes such as firefly 
luciferase (Simpson and Hammond 1991); limiting the utility of detergents in 
investigation of aggregation-based inhibition in such scenarios. 
 It is possible to detect aggregation-based non-specific inhibition by 
determining the IC50 value of a compound at different enzyme concentrations. If the 
enzyme kinetics follows the Michaelis-Menten model, the IC50 should be invariant 
with respect to enzyme concentration, since the latter is negligible compared to 
substrate and inhibitor concentration. However this does not hold good for 
‘aggregators’ as the effective concentration of the inhibitory species would be much 
lower when compared to a classical inhibitor that binds with a stoichiometry of 1:1 
(Shoichet 2006). Thus increasing the enzyme concentration would cause a decrease in 
compound potency as the number of enzyme molecules would no longer be 
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significantly lower than the number of aggregate particles. Testing sensitivity to 
enzyme concentration is a convenient means of identifying aggregation-based 
inhibition if the assay format is sensitive enough to measure enzyme activity over a 
large range of enzyme concentration and enzyme kinetics are well characterized.  
Researchers have suggested that it might be useful to flag or eliminate 
aggregate-forming inhibitors from compound libraries by either testing for detergent-
sensitive inhibition against a model enzyme such as β-Lactamase or testing for 
inhibition of a panel of unrelated enzymes. But a compound that inhibits one target 
non-specifically might well be a potent, specific inhibitor of another target and a 
compound that aggregates at a higher concentration may have legitimate biological 
activity at lower concentrations (McGovern et al. 2003; Seidler et al. 2003). In 
addition, whether or not a compound will act via an aggregation-based mechanism is 
dependent on the properties of the compound itself, the assay conditions (Ferreira et 
al. 2009; Jadhav et al. 2010) and the protein target (Giannetti et al. 2008). For these 
reasons, and because compounds that aggregate are structurally diverse (McGovern et 
al. 2002), interference due to aggregate-based inhibition might need to be empirically 
determined for a given assay (Inglese et al. 2007).   
Techniques such as dynamic light scattering or electron microscopy have 
been in use to directly observe or measure aggregate particles. However, these 
methods are typically low throughput (McGovern et al. 2003; Frenkel et al. 2005). 
There have been other approaches such as NMR-based detection (Dalvit et al. 2006), 
surface plasmon resonance based biosensors (Giannetti et al. 2008),  and photonic 
crystal biosensor microplates (Chan et al. 2009) to identify aggregate-forming 
inhibitors by measuring binding of compounds to the target enzyme.  In addition to 
the lack of validation of these methods in an actual HTS campaign, they are resource 
intensive and require use of specialized apparatus. 
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1.5 Aim of the project 
 
The early and relatively less costly elimination of undesirable or intractable 
lead classes such as aggregate-forming inhibitors is of significant value before 
extensive medicinal chemistry and pharmacokinetic profiling efforts are initiated.  
The aim of this project, therefore, is to investigate generic mechanisms to detect 
aggregation-based inhibition.  
While there are many techniques being used currently such as sensitivity to 
detergent or enzyme concentration; as outlined in the previous section, there are 
circumstances under which they may not be useful.  It would be of interest to apply 
these techniques to actual HTS programs to establish viability of application. 
Furthermore, a generic assay that could be applied to any HTS campaign to eliminate 
inhibitors acting via an aggregation-based mechanism would be of great benefit.   
Recently, a potential generic assay for detection of aggregation-based false 
positives based on the pronounced capillarity of colloidal solutions in the high-
density, multiwell plates used in HTS has been developed (Cai and Gochin 2007). 
Unlike a regular spectrophotometer, where the light path is horizontal and does not 
pass through an air-water interface, the principle of this assay is based on the effect of 
curved meniscus on spectrophotometric measurement using a plate reader with 
vertical light path. The shape of the meniscus has a significant effect on fluorescence 
intensity when detected using a top read fluorescence plate reader due to the light 
path of the device being dependent on the whether the liquid surface is curved or flat 
(Cottingham et al. 2004). The effect is normally avoided in HTS by adding a small 
amount of non-denaturating surfactant to the assay reagents, but if no detergent is 
present, the colloidal particles reduce the surface tension and the resulting change in 
the shape of the meniscus can then be quantified. The viability of this approach was 
demonstrated with a handful of known ‘aggregators’ and ‘non-aggregators’. Good 
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separation was observed between the two classes of compounds and Z’-factor of 0.76 
was reported for the assay (Cai and Gochin 2007). 
The aim of this project is to evaluate the above described meniscus-based 
assay with regard to its applicability in real-life HTS of enzyme targets and assess 
predictability and correlation with more frequently used methods such as sensitivity 
to detergent or enzyme concentration, dynamic light scattering, multiple enzyme 
inhibition etc.  As test cases, inhibitors of three different enzymes: E. Cloacae β-
Lactamase, M. tuberculosis Pantothenate kinase (PanK), and Dengue virus RNA-














2. Materials and Methods 
2.1 β-Lactamase primary screen and secondary assays 
2.1.1 Primary screen 
Purified E. cloacae P99 β-Lactamase (Sigma) was used in all experiments. 
The assay buffer consisted of 25mM PIPES/KOH, pH 7, 10% (v/v) glycerol, 1mM 
dithiothreitol, and 2mM MgCl2 (Ryan et al. 2003). The compound library 
Novartis2008 (Novartis Institute for Tropical Diseases), which was used in the β-
Lactamase screen, consisted of 8272 compounds. Benzo(b)thiophene-2-boronic acid 
(BZBTH2B), purchased from Sigma, served as the reference inhibitor for the 
enzyme. Required volumes of compounds and controls were transferred to the assay 
plates from stock solutions stored in 96-well polypropylene plates (Corning Costar) 
using the Mosquito liquid handling system (TTP Labtech). All compounds were 
screened at 20µM in single point. Assays were performed in 384-well clear plates 
(Corning Costar). Each assay plate contained compounds in columns 1-22; and 16 
wells each of the total (DMSO vehicle) and blank (100µM BZBTH2B) controls in 
columns 23 and 24. Enzyme and substrate concentrations were optimized to obtain 
linear reaction progress curves within a 5 min time course. The enzyme was present 
at 2.5nM in a final reaction volume of 50µl. Reactions were initiated by addition of 
the chromogenic substrate CENTA (Invitrogen) at a final concentration of 25µM. 
CENTA hydrolysis was monitored at room temperature by measuring absorbance at 
405nm on plate reader (Safire2, Tecan). The enzyme activity was calculated as mean 
OD/min.  
2.1.2 Secondary assays using chromogenic substrate 
  Using the same assay conditions as described above (enzyme and substrate 
present at 2.5nM and 25µM respectively in a final reaction volume of 50µl), chosen 
compounds were subjected to dose-response studies. Each assay plate contained 
 21 
 
compound dilutions in columns 2-23, and 16 wells each of the total (DMSO vehicle) 
and blank (100µM BZBTH2B) controls in columns 1 and 24. Dose-response curves 
contained 8 concentrations of compounds obtained using 3-fold serial dilution. 
Freshly prepared solutions of Tween-20 (Sigma), Triton X-100 (Thermo Scientific) 
and CHAPS (Amresco) were added to the enzyme preparation at the specified 
concentrations in the detergent (+) dose-response studies. 
2.1.3 Secondary assays with fluorometric readout 
For the fluorometric procedure, soluble fluorocillin green (Invitrogen) was 
used as substrate in the same assay buffer used in the primary screen. The solid 
fluorocillin substrate was dissolved in DMSO as per manufacturer’s instructions and 
then diluted in assay buffer.  Enzymatic hydrolysis of the lactam ring of fluorocillin 
yields a green fluorescent product which can be measured at wavelengths of 495 nm 
(excitation) and 525 nm (emission). Dose-response curves containing 8 
concentrations of 3-fold serially diluted compounds were obtained in 384-well black 
plates (Corning Costar) under the following reaction conditions: (1) 0.5nM enzyme in 
assay buffer with no detergent, (2) 0.5nM enzyme with assay buffer containing 
0.005% Tween-20 and (3) 5nM enzyme in assay buffer with no detergent. In all 
reactions, substrate was present at 2.5µM in a final reaction volume of 50µl. Each 
assay plate contained compound dilutions in columns 2-23, and 16 wells each of the 
total (DMSO vehicle) and blank (100µM BZBTH2B) controls in columns 1 and 24. 
Enzyme activity was measured at room temperature over the course of 5 min and 
100s for 0.5nM and 5nM of enzyme, respectively, on an Infinite M1000 plate reader 
(Tecan).  
2.1.4 Data analysis 
  Primary screen data were analyzed in IDBS ActivityBase. Z-factors were 
calculated based on the means of the total and blank controls using the formula 
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described previously (see Introduction). Percent inhibition was computed from the 
mean values of the total (uninhibited) and blank (100% inhibition) controls using the 
formula: % Inhibition = 100*(1-((meansample- meanblank)/(meantotal- meanblank))). Dose-
response curves were analyzed using GraphPad Prism 5 (GraphPad Software). IC50 
values were determined using a nonlinear regression fit assuming a sigmoidal dose–
response model with variable slope.  
2.1.5 Dynamic light scattering analysis 
Measurements were performed using a Zetasizer Nano (Malvern Instruments) 
with a He-Ne laser (633 nm) and 173° collecting optics. The software used to collect 
and analyze the data was the Dispersion Technology Software version 5.03 (Malvern 
Instruments). β-Lactamase assay buffer (25mM PIPES/KOH, pH 7, 10% (v/v) 
glycerol, 1mM dithiothreitol, and 2mM MgCl2) was filtered using a 0.2-micron pore 
size filtration unit (Millipore) before using it to dilute compounds. Disposable solvent 
resistant cuvettes (ZEN0040, Malvern) were used for measurements. The solvent 
builder feature of the software was used to estimate viscosity and refractive index of 
the assay buffer. Samples were equilibrated for 2 min before measurements at room 
temperature. The number of scans (ranging from 12-25) was determined by the DLS 
software based on the quality of the sample. The fluctuations in scattering intensity 
for each sample were averaged by the software, neglecting outliers due to 
contaminants such as dust, to yield the size distribution for that sample. For each 
compound, three independent measurements were made. 
2.2 DENV RdRp assay principle, hit selection and follow-up assays 
2.2.1 Assay principle, compound screening and hit selection 
 A novel fluorescence-based alkaline phosphatase-coupled polymerase assay 
was recently developed at the Novartis Institute for Tropical Diseases 
(Niyomrattankit et al. 2011) to discover new inhibitors of dengue virus RNA-
 23 
 
dependent RNA polymerase (DENV RdRp). The assay involves use of an adenosine 
nucleotide modified by attaching the 2′-[2-benzothiazoyl]-6′-hydroxybenzothiazole 
(BBT) fluorophore group to the γ-phosphate (BBT-ATP); and 3’UTR-U30 RNA as 
substrates. During polymerase reaction, adenosine monophosphate is incorporated 
into the RNA resulting in the release of non-fluorescent BBT-PPi, the RdRp reaction 
by-product. Subsequent treatment of the reaction with Calf Intestinal Alkaline 
Phosphatase (CIP) in high pH buffer terminates RdRp activity and liberates highly 
fluorescent BBT molecule from BBT-PPi. Measurement of the final reaction product 
serves as an indirect measure of RdRp activity. 
  A compound library of diverse structures selected from various vendors, 
comprising 40,572 compounds; was used in a pilot screen to find compounds active 
against DENV RdRp (Niyomrattanakit et al. 2011). The DENV non-structural protein 
5 (NS5) protein of Dengue virus serotype 4 containing the RdRp domain was 
expressed as described. BBT-ATP was synthesized by and purchased from Jena 
Bioscience GmbH. Reference inhibitor 3’dATP, which functions as a chain 
terminator, was purchased from Trilink Biotech. RNA substrate 3’UTR-U30 was 
purchased from Dharmacon. The CIP enzyme was purchased from New England 
Biosciences. The screen was performed in 384-well black plates in a total of 118 
plates. Each plate contained compounds in columns 1-22 and 16 wells each of the 
total (DMSO vehicle) and blank (20µM 3’dATP) controls in column 23 and 24. The 
polymerase reaction was run in optimized buffer for NS5 RdRp consisting of 50mM 
Tris-Cl (pH 7.0), 1mM MnCl2, and 0.01% Triton X-100. The NS5 protein and the 
3’UTR-U30 substrate were mixed in assay buffer at concentrations of 40nM and 
100nM respectively and incubated at room temperature for 30 min.  To each well of 
the assay plate containing either compound or control, 5µl of the above solution was 
added. Reaction was initiated by addition of 5µl of the BBT-ATP substrate at a 
concentration of 4µM. The final reaction volume of 10µl containing 20nM RdRp, 
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50nM 3’UTR-U30 RNA substrate and 2µM BBT-ATP was incubated for 1hr at room 
temperature followed by addition of 10µl of stop buffer (25nM CIP, 200mM NaCl, 
25mM MgCl2, 1.5M deoxyethanolamine) to inactivate RdRp and to hydrolyze the 
BBT-PPi. Plates were read after 1 hr incubation at room temperature to ensure 
complete hydrolysis of BBT-PPi by CIP. The fluorescence was measured at 
wavelengths of 422 nm (excitation) and 566 nm (emission) on an Infinite M1000 
plate reader.  
The Z-factor averaged from 118 plates was found to be 0.81 with SD value at 
0.05.  Compounds with greater than 30% inhibition (calculated from 3×SD of 
sample) were selected as hits for reconfirmation (407 compounds in total). All 
compounds that auto-fluoresced or inhibited the coupling enzyme CIP were 
eliminated from the hit list. The remaining compounds were subjected to liquid 
chromatography-mass spectrometry (LC-MS) analysis to confirm compound purity. 
A total of 30 compounds passed all the required selection filters and these 30 
compounds are the subject of the various follow-up assays performed in this study. 
2.2.2 Testing inhibition potency of hits in different detergents 
The 30 compounds chosen for follow-up were subjected to dose-response 
studies in the presence of different detergents in the assay buffer. Desired amounts of 
freshly prepared Triton X-100, Brij-35 (Thermo Scientific) and CHAPS were 
included in the assay buffer (in place of the 0.01%Triton X-100 present in the assay 
buffer used in the pilot screen). Dose-response curves containing 10 concentrations of 
3-fold serially diluted compound were obtained in the presence of low and high 
amounts of the above mentioned detergents in the assay buffer (2 concentrations of 
each detergent giving 6 dose-response curves for each compound). Each assay plate 
contained compounds in columns 1-11 and 14-23, and 32 wells each of total (DMSO 
vehicle) and blank (20µM 3’dATP) controls in columns 1, 12, 13 and 24. All other 
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reaction parameters such as RdRp, 3’UTR-U30 and BBT-ATP concentrations, 
incubation times, and reaction termination procedure were identical to conditions 
used in the pilot screen.  
2.2.3 Testing inhibition potency of hits at varying enzyme concentrations 
Dose-response curves were obtained at 10nM and 100nM RdRp in order to 
test the effect of enzyme concentration on inhibition potency. The concentration of 
the BBT-ATP substrate was kept constant at final concentration of 2µM and the 
buffer composition was the same as the pilot screen except for the Triton X-100 
concentration (0.002% instead of 0.01%) in all reactions described below.  For 
reactions involving 10nM RdRp, compounds were tested separately at two different 
RNA concentrations. At concentrations of 50nM and 150nM 3’UTR-U30 RNA, 
reactions were incubated at room temperature for 60 min and 100 min respectively 
before inactivation by CIP. For reactions involving 100nM RdRp, 150nM of 3’UTR-
U30 RNA was used and reaction was allowed to progress for 20 min before 
termination by CIP. Dose-response curves contained 10 concentrations of each 
compound obtained by 3-fold serial dilution. Each assay plate contained compounds 
in columns 1-11 and 14-23; and 32 wells each of total (DMSO vehicle) and blank 
(20µM 3’dATP) controls in columns 1, 12, 13 and 24.  
2.2.4 Effect of Triton X-100 on kinetic constants of DENV RdRp 
 Apparent Km and Vmax values for 3’UTR-U30 RNA substrate were obtained at 
different Triton X-100 concentrations by plotting the observed BBT production as a 
function of RNA concentrations. RNA concentrations ranging from 0-70 nM were 
assayed at 10nM RdRp with BBT-ATP concentration at 2µM. Time course of the 
reaction were analyzed by linear regression to obtain the slopes in RFU/min. These 
values were then converted to pmole/min using a standard curve of BBT obtained as 
described previously (Niyomrattanakit et al. 2011). Using GraphPad Prism 5 
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software, initial rates (v) of enzyme activity were fit into the Michaelis–Menten 
equation v =Vmax {[S]/([S]+Km
app)} where the Vmax and Km
app are the maximum 
velocity and Michaelis–Menten constant, respectively, and [S] is the substrate 
concentration. 
2.3 Selection of compounds from PanK hit list  
A high throughput screen of 1.2 million compounds from the Novartis 
Compound Archive was performed recently against the M. tuberculosis Pantothenate 
Kinase (PanK) enzyme (Habig et al. 2009). Briefly, compounds were tested for 
inhibition of PanK activity in a luminescence based assay (using the Kinase-Glo Plus 
kit by Promega). To eliminate readout artifacts, primary hits were re-tested in a 
polarization-based assay for detection of ADP (employing the Transcreener KINASE 
Plus Assay kit by BellBrook Labs). For both formats, standard reaction buffer 
contained 50 mM HEPES (pH 7.5), 4 mM MgCl2, 2 mM EGTA, and 50 mM NaCl. 
The 2022 compounds that showed a defined dose-response curve in both readouts 
were tested for shift in potency on variation of enzyme concentration and addition of 
detergent to the assay buffer. Based on the assumption that ATP-competitive 
inhibitors interact specifically with the enzyme, the authors used ATP-competitive 
inhibitors among the hits to assess the feasibility of using detergent or enzyme-
concentration sensitivity to identify non-specific inhibitors. A cross-comparison 
revealed that the potency of 535 ATP-competitive compounds was sensitive to 
detergent concentration whereas the potency of only 103 of 788 ATP competitive 
compounds was substantially affected by an increase in enzyme concentration. Since 
enzyme concentration sensitivity appeared to be more predictive than detergent 
sensitivity in identification of non-stoichiometric inhibitors of PanK, only those hits 
that were found to be insensitive to enzyme concentration were analyzed by NMR to 
confirm binding to enzyme. 
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Due to the fact that these compounds have been the subject of detailed 
analyses, their mode of inhibition was known. This made them ideal candidates for 
determination of predictive value of different techniques to detect non-specific 
inhibition. Based on compound availability, a subset of 15 enzyme-concentration 
sensitive and 26 enzyme-concentration insensitive PanK hits were chosen from hit list 
and obtained from the Novartis Compound Archive. These 41 compounds and a 
reference inhibitor of PanK, acetyl coenzyme A (Acetyl CoA); were used in other 
assays as described below.  
2.4 Measurement of change in meniscus  
The assay was first optimized in the β-Lactamase assay buffer with dyes such 
as fluorescein (Fluka) or lucifer yellow (Invitrogen); which allowed quantification of 
change in meniscus shape due to the effect light-path length on fluorescence emission 
through a curved liquid surface. For both dyes, the fluorescence of the dye measured 
in assay buffer containing 1mM Triton X-100 or 1mM Tween-20 (control buffer) was 
found to be between 40-50% lower than fluorescence of the dye in assay buffer 
without detergent. Fluorescein dye was chosen for compound measurements based on 
the recommendation of the authors who developed this assay (Cai, personal 
communication). 
A concentration of 0.1µM fluorescein was found to be optimal for use in all 
assay buffers tested in this study (β-Lactamase, DENV RdRp and PanK assay 
buffers). Hits of all three enzymes (14 hits from β-Lactamase primary screen, 30 
DENV RdRp hits and 41 hits chosen from the PanK hit list) were tested at 20µM in 
their respective assay buffers. Reference inhibitors for each enzyme were also tested 
(β-Lactamase - BZBTH2B, DENV RdRp - 3’dATP and PanK- Acetyl CoA).  
Compounds were added to 384-well black plates followed by addition of 30µl of 
either assay buffer or control buffer (assay buffer with 1mM Triton X-100 or 1mM 
Tween-20). After allowing the signal to stabilize for 30min, fluorescence was 
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measured at wavelengths of 490 nm (excitation) and 514 nm (emission) on an Infinite 
M1000 reader. Relative fluorescence was measured as a ratio of the observed 
fluorescence of dye in assay buffer to that in control buffer. Each compound was 


























3. Results  
3.1 β-Lactamase primary screen and follow-up assays 
3.1.1 Hit Selection and re-confirmation 
A total of 8272 compounds from compound library Novartis2008 were 
screened against E. cloacae β-Lactamase in detergent-free conditions in 24 assay 
plates. Z-factor remained above the 0.5 cut-off across all plates (Fig. 5). Average Z-
factor for the 24 assay plates was 0.71 with an SD value at 0.05.  
 
 




The distribution of β-Lactamase inhibition for this library was found to be 
right skewed (Fig. 6). The interquartile range for the distribution of percent inhibition 
(range containing 50% of compounds) was found to show a difference of 10.6 
percentage points (-5 to 5.6%), indicating screen quality was good. Based on a 40% 
inhibition cut-off (see Discussion), 19 compounds were selected as hits, 
corresponding to a hit rate of 0.23%. Fourteen compounds were available upon re-
ordering from the Novartis Compound Archive. All 14 hits were found to inhibit β-
Lactamase in a dose-dependent manner, giving a re-confirmation rate of 100%. Of 
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the 14 hits, 11 had steep dose-response curves, indicated by a Hill co-efficient lower 





































Figure 6: Histogram of normalized inhibition data of compound library tested 
against β-Lactamase. Distribution was analyzed using GraphPad Prism 5. 
 
 
3.1.2 Detergent sensitivity of inhibition potency of β-Lactamase hits 
Hits were subjected to dose-response analysis in the presence of detergent 
(Tween-20, Triton X-100 and CHAPS) to determine if inhibition potency was 
sensitive to detergent. Of the 14 hits, 13 were found to display detergent-sensitive 
inhibition in all three detergents tested (Table 2). In the presence of detergent 
(0.004% Tween-20, 0.007% Triton X-100, 0.3% CHAPS) at concentrations below 
CMC; these 13 compounds either failed to inhibit the enzyme or had a greater than 3-




Table 2: IC50 values of hits from β-Lactamase screen in the absence and presence 
of detergent. Concentration of enzyme and substrate in all assays was 2.5nM β-
Lactamase and 25µM CENTA respectively. Tween-20, Triton X-100 and 








IC50 shift in detergent 
Tween-20 Triton X-100 CHAPS 
BZBTH2B 7.11 -1.00 No change ↑1.2-fold ↓1.4-fold 
BLAC-1 15.23 -1.02 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-2 2.00 -14.34 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-3 3.86 -3.90 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-4 8.00 -4.99 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-5 19.37 -4.09 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-6 4.81 -2.47 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-7 7.02 -13.31 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-8 >20 -0.97 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-9 18.40 -3.48 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-10 6.45 -14.06 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-11 14.10 -1.38 ↑2.6-fold ↑2-fold ↑1.1-fold 
BLAC-12 7.01 -12.43 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-13 3.03 -3.78 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
BLAC-14 7.30 -11.91 ↑ >3-fold ↑ >3-fold ↑ >3-fold 
 
 
The inhibition potency of the reference inhibitor BZBTH2B was not affected 
by the presence of detergent. BZBTH2B displayed well-defined dose response curves 
in the presence of all detergents (Fig. 7A). A known aggregate-former 
tetraiodophenolphthalein (McGovern et al. 2002), as expected, did not inhibit the 
enzyme in the presence of detergent (Fig. 7B). Among the hits only one compound, 
BLAC-11, inhibited the enzyme in a dose-dependent manner in the presence of all 
three detergents (Fig. 8A). All other hits displayed tetraiodophenolphthalein-like 








Figure 7: Dose-response curves of A) BZBTH2B, a reference inhibitor of E. 
cloacae β-Lactamase and B) Tetraiodophenolphthalein, a known aggregate-
forming inhibitor of β-Lactamase. All dose-response curves contained 8 
concentrations from highest concentration of 100µM diluted serially 3-fold. Each 









Figure 8: Dose-response curves showing inhibition of β-Lactamase by A) BLAC-
11 and B) BLAC-13. All dose-response curves contained 8 concentrations from 
highest concentration of 20µM diluted serially 3-fold. Each data point represents 








3.1.3 Enzyme-concentration sensitivity of inhibition potency of β-Lactamase hits 
When enzyme concentration was increased 10-fold (2.5nM to 25nM), Z’-
factors with chromogenic substrates such as CENTA and Penicillin-G were less than 
0 (data not shown). The chromogenic assay format was not found to be sensitive 
enough to allow accurate quantification of reaction rate at higher enzyme 
concentrations.  Therefore, a fluorometric assay format was used to test sensitivity of 
inhibition potency at increased enzyme concentrations. At β-Lactamase 
concentrations of 0.5nM and 5nM, the assay could be performed using identical 
substrate concentrations. Of the 14 hits, 10 hits had greater than 3-fold IC50 shifts and 
one hit had a fold-change very close to 3. The sensitivity of compound potency to 
enzyme concentration corresponded well to detergent sensitivity measured under the 
same assay format (Table 3).  
 
Table 3: IC50 values of hits from β-Lactamase screen in the fluorometric assay 
format. Concentration of Fluorocillin in all assays was 2.5uM. Tween-20 















BZBTH2B 0.43 -1.05 ↑1.22-fold ↑1.33-fold 
BLAC-1 0.61 -0.51 ↑ >3-fold ↑ >3-fold 
BLAC-2 1.87 -0.81 ↑ >3-fold ↑ >3-fold 
BLAC-3 0.93 -1.69 ↑ >3-fold ↑ >3-fold 
BLAC-4 5.05 -2.14 ↑2.55-fold ↑ >3-fold 
BLAC-5 13.85 -1.67 ↑ >3-fold ↑ >3-fold 
BLAC-6 1.90 -1.26 ↑ >3-fold ↑ >3-fold 
BLAC-7 6.83 -2.17 ↑2.60-fold ↑ >3-fold 
BLAC-8 52.38 -0.43 ↑ >3-fold ↑ >3-fold 
BLAC-9 9.86 -2.77 ↑ >3-fold ↑ >3-fold 
BLAC-10 2.53 -3.75 ↑2.92-fold ↑ >3-fold 
BLAC-11 13.32 -0.86 ↑2.19-fold ↑2.35-fold 
BLAC-12 1.71 -3.18 ↑ >3-fold ↑ >3-fold 
BLAC-13 1.47 -1.42 ↑ >3-fold ↑ >3-fold 
BLAC-14 3.56 -1.30 ↑ >3-fold ↑ >3-fold 
 
Only 5 of 14 compounds displayed steep dose-response curves in the 
fluorometric assay format opposed to 11 of 14 hits in the assay with the chromogenic 
substrate indicating that the Hill co-efficients of dose-response curves of the hits were 
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not in complete agreement between the two assay formats. Detergent sensitivity of 
inhibition potency, measured in the form of IC50 changes, was found to be consistent 
for all hits in both assay formats  (Tables 2 and 3); with 93% of hits found to display 
detergent-sensitive inhibition in the chromogenic and fluorogenic assays. 
3.1.4 Dynamic light scattering analysis of β-Lactamase hits 
β-Lactamase hits were subjected to DLS analysis in order to measure the size 
of aggregate particles in solution. For some of the hits, particle sizes were found to be 
between 200-1000 nm in diameter. However, the software reported accompanying 
error messages indicating poor data quality. In addition, for the same compound, the 
variation in measured particle size was observed to be high as 40% (e.g., 250 nm in 
one measurement and 600nm in another measurement). The measurements were also 
confounded by high signal to noise ratios. 
Since fitting algorithms cannot always distinguish high from low quality raw 
data, they generally give a size distribution for every sample, even for raw data that 
does not fit DLS criterion. Thus, instead of relying solely on particle size 
distributions, autocorrelation functions (plotted as correlograms) should be 
scrutinized as they are reliable indicators of data quality. A high quality correlogram 
can be described as having high amplitude (Y intercept) and a smooth exponential 
decay to a single, flat, and zero baseline (Malvern, Technical Support Library). 
Correlograms that deviate from the norm usually indicate that the raw data was of 
sub-optimal quality. For a majority of the β-Lactamase hits, quality of raw data was 





Figure 9: DLS correlogram of BLAC-1 at A) 20µM and B) 66µM as measured 
with a Malvern Zetasizer Nano ZS dynamic light scattering instrument in assay 
buffer. Red and green lines represent independent measurements of the sample. 
 
 
For example, repeated measurements of compound BLAC-1 at 20µM and 
66µM gave inconsistent results with particle size diameters ranging from 200-950 
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nm. The correlogram of BLAC-1 (Fig. 9) was suggestive of low intensity scattering 
even at a compound concentration of 66µM. In the dose-response assay, the 
maximum compound concentration used was 20µM and the compound BLAC-1 had 
both enzyme-concentration and detergent-dependent potency shifts indicative of 
aggregation-based inhibition. It is possible that the amount of scattered light from the 
aggregate particles was not sufficient to make successful measurements in a DLS 
assay.  
Other compounds had noisy correlograms indicative of high signal to noise 
ratios. As a representative of these, the correlograms of compound BLAC-2 are 
depicted in Figure 10. The correlograms showed presence of noise and had elevated 
baselines suggestive of either large particle sizes outside the range of the instrument 
or number fluctuations during the measurement. Despite optimizing run time and 
collecting data for extended periods, the correlogram quality could not be improved. 
Either the particles formed are too large to be detected by the instrument or the nature 






Figure 10: DLS correlogram of BLAC-2 at A) 20µM and B) 66µM as measured 
with a Malvern Zetasizer Nano ZS dynamic light scattering instrument in assay 




3.2 Follow-up of DENV RdRp pilot screen 
 
3.2.1 Detergent sensitivity of inhibition potency of DENV RdRp hits 
 
As DENV RdRp displayed poor activity in the absence of detergent, the pilot 
screen was run in assay buffer containing 0.01% Triton X-100 (Niyomrattanakit et al. 
2011).  To ensure that the nature of detergent did not affect inhibition, the hits were 
re-tested in low concentrations of three detergents – Triton X-100, Brij-35 and 
CHAPS. The re-testing was done at the minimum concentration of detergent (below 
its CMC) that was required to observe a good signal window in the RdRp assay. 
 The inhibitory potency of a specific inhibitor of the DENV RdRp, 3’dATP, 
did not vary significantly in the different detergents. Additionally, it was found that 
the 30 compounds retained activity in all three detergents (Table 4), indicating that 
inclusion of a low concentration of detergent in the assay buffer did not affect the 
inhibitory potency of RdRp hits.  However, some hits (RDRP-1, 2, 8, 16, 20 and 23) 
appeared to be a lot more potent in buffer containing CHAPS compared to Brij-35.   
It was observed that almost all of the hits had dose-response curves with good 
Hill co-efficients (greater than -2) in the presence of every detergent tested. The value 
of the Hill-coefficient varied for the same compound tested in buffer containing 
different detergents. No compounds had steep dose response curves in assay buffer 
containing CHAPS. While 5 compounds had high Hill co-efficients in the presence of 










Table 4: IC50 values of DENV RdRp hits in the presence of different detergents 
in the assay buffer. The concentrations of the detergents were 0.004% Brij-35, 
0.002% Triton and 0.03% CHAPS. Enzyme and substrate concentrations were 
the same as the pilot screen. 
Compound 
code 













3’ dATP 0.15 -0.75 0.30 -0.86 0.38 -0.78 
RDRP-1 >20 -1.90 20.13 -11.81 7.42 -1.52 
RDRP-2 >20 -0.87 12.91 -0.81 10.43 -0.99 
RDRP-3 17.30 -1.43 14.07 -0.85 9.07 -0.98 
RDRP-4 13.07 -1.41 11.00 -0.80 7.54 -0.95 
RDRP-5 11.60 -1.43 7.60 -0.80 5.59 -0.99 
RDRP-6 7.21 -1.13 4.81 -0.72 3.63 -0.83 
RDRP-7 14.29 -1.62 14.97 -0.77 9.70 -1.08 
RDRP-8 >20 -0.70 15.77 -0.67 7.77 -1.00 
RDRP-9 14.97 -1.09 8.38 -0.99 5.84 -1.09 
RDRP-10 22.14 -1.63 17.44 -0.99 9.12 -1.04 
RDRP-11 10.71 -1.33 9.61 -0.85 4.61 -1.39 
RDRP-12 18.50 -1.54 16.47 -0.89 8.45 -1.46 
RDRP-13 18.34 -2.25 18.59 -1.23 12.53 -1.54 
RDRP-14 14.09 -1.62 13.15 -1.38 10.41 -1.53 
RDRP-15 17.57 -3.92 26.00 -1.23 14.10 -1.67 
RDRP-16 13.48 -1.17 7.13 -0.96 3.07 -0.99 
RDRP-17 9.65 -1.62 4.55 -0.75 2.92 -0.92 
RDRP-18 17.53 -1.05 11.63 -0.95 9.36 -1.44 
RDRP-19 19.90 -1.06 10.80 -1.15 6.31 -1.15 
RDRP-20 20.25 -11.66 10.19 -0.79 1.84 -0.96 
RDRP-21 13.48 -1.22 8.99 -0.94 6.39 -1.10 
RDRP-22 4.74 -0.70 3.43 -0.55 2.06 -0.60 
RDRP-23 17.50 -3.38 15.48 -0.60 3.12 -0.87 
RDRP-24 12.95 -1.44 15.47 -0.95 7.55 -1.14 
RDRP-25 13.99 -3.04 9.24 -0.99 4.02 -1.12 
RDRP-26 21.96 -1.47 11.58 -1.62 7.04 -1.69 
RDRP-27 11.84 -1.45 11.88 -1.08 7.20 -1.22 
RDRP-28 6.27 -1.24 6.90 -1.10 4.19 -1.28 
RDRP-29 15.42 -1.47 6.40 -1.18 4.59 -1.51 
RDRP-30 9.63 -1.19 10.54 -0.98 5.72 -1.11 
 
Detergent-dependent potency shifts were investigated by obtaining the IC50 
values of the hits in increased amounts of detergent. To account for minor variations 
of the IC50 values of compounds in the presence of different detergents (Table 4), a 5-
fold increase in IC50 was used as a cut-off was used to assign whether or not a 
compound experienced a significant decrease in potency at increased concentrations 
of detergent. For a total of 30 hits investigated, inhibition of 43% of the compounds 
was sensitive to Brij-35, 54% to Triton X-100 and 20% to CHAPS (Table 5). 
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Prevalence of hits displaying detergent-sensitive inhibition of DENV RdRp was 
found to be lower compared to 93% prevalence of detergent-sensitive inhibitors 
among β-Lactamase hits.  
 
Table 5: Changes in IC50 values of DENV RdRp hits at higher concentrations of 
detergent. Reaction conditions were identical to those in the protocol followed 
for the pilot screen.  









3’ dATP 1.6 1.4 1.5 
RDRP-1 >5 >5 3.22 
RDRP-2 2.88 >5 4.12 
RDRP-3 3.69 4.43 >5 
RDRP-4 >5 >5 3.81 
RDRP-5 >5 3.17 4.71 
RDRP-6 >5 >5 >5 
RDRP-7 3.45 >5 4.56 
RDRP-8 >5 >5 3.54 
RDRP-9 1.68 >5 4.30 
RDRP-10 >5 >5 4.14 
RDRP-11 3.17 3.92 2.96 
RDRP-12 2.74 1.51 3.81 
RDRP-13 4.52 1.31 >5 
RDRP-14 3.91 >5 4.28 
RDRP-15 >5 >5 1.19 
RDRP-16 >5 >5 3.99 
RDRP-17 >5 >5 4.22 
RDRP-18 1.24 0.76 1.53 
RDRP-19 2.69 1.90 2.56 
RDRP-20 >5 >5 >5 
RDRP-21 1.95 1.65 1.95 
RDRP-22 >5 >5 1.88 
RDRP-23 >5 >5 >5 
RDRP-24 1.22 0.97 1.50 
RDRP-25 3.59 >5 >5 
RDRP-26 >5 0.06 2.12 
RDRP-27 2.38 1.61 1.77 
RDRP-28 1.60 1.20 1.42 
RDRP-29 1.11 4.42 1.54 








3.2.2 Enzyme-concentration sensitivity of inhibition potency of DENV RdRp hits 
 
Table 6: Enzyme-concentration dependent changes in IC50 values of DENV 
RdRp hits. All reactions were performed in assay buffer containing 0.002% 


















3’ dATP 0.58 0.84 1.1 0.76 
RDRP-1 18.96 >20 1.36 0.67 
RDRP-2 7.86 3.22 >5 >5 
RDRP-3 8.31 3.14 >5 >5 
RDRP-4 6.92 2.41 >5 >5 
RDRP-5 5.47 1.37 >5 >5 
RDRP-6 3.30 1.60 >5 >5 
RDRP-7 11.67 4.36 4.25 >5 
RDRP-8 5.84 2.29 >5 >5 
RDRP-9 4.45 1.94 >5 >5 
RDRP-10 8.15 4.86 >5 >5 
RDRP-11 4.52 1.84 >5 >5 
RDRP-12 12.15 4.61 3.47 >5 
RDRP-13 18.22 6.29 2.45 >5 
RDRP-14 15.15 4.75 1.80 >5 
RDRP-15 18.38 4.58 4.30 >5 
RDRP-16 4.30 0.91 4.91 >5 
RDRP-17 1.86 0.68 >5 >5 
RDRP-18 5.22 4.63 >5 >5 
RDRP-19 3.64 3.03 >5 >5 
RDRP-20 3.57 1.35 >5 >5 
RDRP-21 4.05 3.22 >5 >5 
RDRP-22 0.83 0.59 >5 >5 
RDRP-23 6.60 1.52 >5 >5 
RDRP-24 5.55 2.94 >5 >5 
RDRP-25 6.75 3.58 >5 >5 
RDRP-26 9.23 2.45 3.22 >5 
RDRP-27 5.49 2.93 >5 >5 
RDRP-28 3.32 3.23 >5 >5 
RDRP-29 5.45 3.97 4.06 >5 
RDRP-30 4.75 2.91 >5 >5 
 
 Sensitivity of inhibition potency to varying enzyme concentrations was 
performed at 10nM and 100nM RdRp under 2 sets of conditions: 1) different 
concentrations of 3’UTR-U30 RNA substrate at each enzyme concentration, and 2) 
identical concentrations of 3’UTR-U30 RNA substrate used at both enzyme 
concentrations. Under the first condition, inhibition potency of 21 out of the 30 hits 
appeared to be sensitive to enzyme concentration while under the second condition; 
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the inhibition of 29 out of 30 hits was significantly attenuated (IC50 increased by 
greater than 5-fold) at the higher enzyme concentration (Table 6). 
3.2.3 Effect of Triton X-100 concentration on enzyme kinetics 
Effect of Triton X-100 was tested as it was the detergent used in the assay 
buffer in the pilot screen and in testing sensitivity of inhibition potency to enzyme 
concentration. The apparent Km and Vmax values of DENV RdRp for the 3’UTR-U30 
RNA substrate were determined in the presence of varying amounts of Triton X-100 
to examine whether the detergent affected the enzyme kinetics. Concentration of the 
second substrate BBT-ATP was kept constant at 2µM in all reactions.  



















Figure 11: Effect of Triton X-100 on apparent Km and Vmax values of DENV 
RdRp. Different 3’ UTR-U30 RNA concentrations (0–70nM) were used to 
determine DENV RdRp activity in the presence of varying amounts of Triton X-
100. Concentration of BBT-ATP substrate was kept constant at 2µM in all 
reactions. Enzyme concentration in all experiments was 10nM. Each data point 
represents the average of 4 measurements.  
 
As shown in Table 7, the Km
app values did not differ significantly with 
detergent concentration but the Vmax
app was slightly higher at decreased Triton X-100 
concentrations (0.016 pmole/min in 0.002% Triton X-100 as opposed to 0.012 
pmole/min in both 0.01% and 0.1% Triton X-100). At all three concentrations of 
Triton X-100, the rate of reaction began to drop at RNA concentrations higher than 
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50nM (Fig. 11). The drop in activity therefore did not appear to be influenced by the 
amount of detergent; rather it seemed to be an effect of RNA concentration (see 
Discussion).  
 
Table 7: The apparent Km and Vmax of the 3’UTR-U30 RNA substrate at different 
Triton X-100 concentrations. Concentration of BBT-ATP substrate was kept 
constant at 2µM in all reactions. Enzyme concentration in all experiments was 
10nM. 
Michaelis-Menten 0.002% Triton X-100 0.01% Triton X-100 0.1% Triton X-100 
Best-fit values       
Vmax (pmole/min) 0.016 0.012 0.012 
Km (µM) 
 
9.36 7.96 10.61 
95% Confidence 
Intervals 
   
Vmax (pmole/min) 0.015 to 0.018 0.011 to 0.013 0.010 to 0.013 
Km (µM) 7.24 to 11.51 5.25 to 10.66 7.10 to 14.12 
 
 
3.3 Investigation of inhibition of unrelated enzymes or a model enzyme as means 
of identification of aggregation-based inhibition 
 
Percentage target inhibition of enzymes E. Cloacae AmpC β-Lactamase, M. 
tuberculosis Nicotinamide adenine dinucleotide synthetase, M. tuberculosis 
Pantothenate Kinase and Dengue virus serotype 4 RNA-dependent RNA polymerase 
by compounds from library Novartis2008 were compared to determine if any 





Figure 12: Comparison of primary screens of various enzymes – E. Cloacae 
AmpC β-Lactamase (Beta-Lactamase), M. tuberculosis Nicotinamide adenine 
dinucleotide synthetase (MTB NadE), M. tuberculosis Pantothenate Kinase 
(MTB PanK) and Dengue virus serotype 4 RNA-dependent RNA polymerase 




β-Lactamase inhibition data for compounds from library Novartis2008 was 
obtained using a chromogenic assay format as described earlier (see Materials and 
Methods). For all other enzymes, the inhibition data for compound library 
Novartis2008 was retrieved from previous Novartis records. Dengue virus serotype 4 
RNA-dependent RNA polymerase activity was measured in an end point read-out 
using a fluorescence-based assay and both M. tuberculosis Nicotinamide adenine 
dinucleotide synthetase and Pantothenate Kinase assays involved a fluorescence 
polarization-based end point read-out. Enzyme assays with different detection 
technologies were chosen to ensure the comparison was not influenced by assay 
readout. As can be seen from Figure 12, except for a slight overlap between hits of M. 
tuberculosis Pantothenate Kinase and Dengue virus serotype 4 RNA-dependent RNA 
polymerase; each enzyme appeared to have a distinct set of inhibitors.  
 
 
Figure 13: Distribution of DENV RdRp hits. Of all 30 hits, inhibition of 20 hits 
was sensitive to at least one of the detergents tested and the other 10 hits were 
detergent-insensitive inhibitors. The numbers on the pie chart fractions 




Figure 14: Distribution of Pantothenate Kinase hits. Of the chosen 41 
compounds, 26 were insensitive to enzyme concentration and 15 compounds 
were significantly less potent (i.e non-specific) when assayed at higher enzyme 
concentrations. The numbers on the pie chart fractions represent how many 
compounds in that category inhibit β-Lactamase. 
 
 Hits from the DENV RdRp and PanK screens (see Materials and Methods) 
were assayed for inhibition of β-Lactamase enzyme activity using identical reaction 
conditions as employed in the β-Lactamase primary screen (see Materials and 
Methods). They were classified as β-Lactamase inhibitors if they inhibited enzyme 
activity by greater than 40%, which was the % cut-off used for hit selection in the 
primary β-Lactamase screen. As can be seen from Figures 13 and 14, inhibition of β-
Lactamase was not a hallmark of compounds that inhibited their respective target 
enzyme non-specifically (determined by sensitivity of inhibition potency to detergent 
or enzyme concentration). Among the PanK hits, five compounds that satisfied the 
stoichiometric considerations for specific inhibition of PanK (IC50 unchanged at 
different PanK concentrations) were found to be inhibitors of β-Lactamase. Among 
the DENV RdRp hits, only 2 of 20 detergent-sensitive hits inhibited β-Lactamase. 
Thus, assaying inhibitory potency of compounds against β-Lactamase did not appear 
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to be indicative of whether a compound inhibited its target enzyme via an 
aggregation-based mechanism. 
 
3.4 Development and validation of change in meniscus shape as a generic assay 
for detection of aggregate formation 
  
In agreement with previous reports (Cai and Gochin 2007), it was observed 
that the liquid surface was nearly flat for buffer solution without detergent and 
formed a concave meniscus upon addition of detergent at a concentration above its 
CMC, an effect that could be observed by the naked eye when the plates were 
examined. The assay signal was found to be robust; fluorescence intensity of the 
fluorescein dye remained stable for up to 4 hours. The gain setting of the fluorescence 
reader was optimized to give a consistent signal window in all assay buffers (β-
Lactamase, DENV RdRp and PanK). Relative fluorescence was measured as a ratio 
of the observed fluorescence of fluorescein dye in the presence of test compound in 
assay buffer to that of the compound in control buffer (assay buffer containing 1mM 
Triton X-100 or 1mM Tween-20). 
Since this assay has never been used in an actual HTS campaign prior to this 
study, cut-offs to classify compounds as ‘aggregators’ had to be derived. For all three 
enzymes, it was found that the reference inhibitors used as controls in the primary 
screens served as useful benchmarks in the measurement of changes in meniscus 
curvature. As expected, by virtue of being known non-aggregating inhibitors, these 
reference inhibitors did not influence the shape of the liquid meniscus and hence did 
not affect the relative fluorescence of the dye.  
Therefore, hits could be classified on the basis of deviation of their relative 
fluorescence ratios from the reference inhibitor ratio. A ratio lower than 3 standard 
deviations from the mean of the ratio derived from multiple measurements of the 
reference inhibitor was used as the cut-off to classify which compounds might be 
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inhibiting the target via an aggregation-based mechanism. Additionally, in 
combination with data from an independent method to determine aggregation-based 
inhibition (such as sensitivity to detergent or enzyme concentration), the cut-offs of 1, 
2 and 3 SD’s away from the reference ratio could potentially be used to assign a rank 
or prioritize which hits to chose for lead optimization. 
 
Figure 15: Relative fluorescence of β-Lactamase hits measured as the ratio of 
top-read fluorescence intensity in assay buffer to control buffer. Compounds 
were assayed at a concentration of 20µM. Compound no. corresponds to 
compound code in Table 2. Sensitive to detergent ( ) means IC50 increased by 
more than 3-fold in the presence of detergent and vice versa in case of 
insensitivity to detergent ( ) Compound no. 15 ( ) is BZBTH2B (specific 
inhibitor of β-Lactamase). From top to bottom, the dotted lines represent 1, 2 
and 3 SD’s respectively from the mean of the BZBTH2B ratio.  
 
 
Among the β-Lactamase hits (Fig. 15), 12 of 14 compounds had relative 
fluorescence ratios smaller than 3 SD’s less than the mean of ratio obtained with 
BZBTH2B, indicating that these compounds formed colloidal particles in the assay 
buffer. The data was in good agreement with the detergent sensitivity tests in which 
all compounds except BLAC-11 (compound no. 11 in Fig 15) displayed 
characteristics of aggregate-based inhibition. Only compound 8 (corresponding to 
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compound code BLAC-8 in Table 2) did not appear to form colloidal particles in 




Figure 16: Relative fluorescence of DENV RdRp hits measured as the ratio of 
top-read fluorescence intensity in assay buffer to control buffer. Compounds 
were assayed at a concentration of 20µM. Compound no. corresponds to 
compound code in Table 4. Sensitive to all detergents( ) implies >5-fold IC50 
increase in Triton X-100, Brij-35 and CHAPS; and vice versa for compounds 
insensitive to all detergent ( ) .  Sensitive to 1/2 detergents ( ) implies >5-fold 
IC50 in one or two but not all of the above mentioned detergents. Compound no. 
31( ) is 3’ dATP (specific inhibitor of DENV RdRp). From top to bottom, the 
dotted lines represent 1, 2 and 3 SD’s respectively from the mean of the 3’dATP 
ratio.  
 
 Among the DENV RdRp hits (Fig. 16), the three compounds which were 
found to have inhibition potency that was sensitive to all detergents (Triton X-100, 
Brij-35 and CHAPS), had relative fluorescence ratios much lower than 3 SD’s from 
the mean of the 3’dATP ratio. Of the 10 hits that did not have significant changes in 
their IC50 values at higher concentrations of detergent, 7 compounds had ratios within 
the 3 SD window and the remaining 3 compounds had ratios in the borderline region. 
Of the 17 hits that had significant changes in their IC50 values in at least one of the 
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three detergents tested; 10 compounds had ratios lower that the cut-off; 2 compounds 
had ratios in the borderline and the remaining 5 compounds had ratios that were not 




Figure 17: Relative fluorescence of MTB PanK hits measured as the ratio of top-
read fluorescence intensity in assay buffer to control buffer. Compounds were 
assayed at a concentration of 20µM. IC50’s of compound no. 1-26 were not 
significantly affected by enzyme concentration and these compounds were 
further characterized by NMR studies. IC50’s of compound no. 27-41( ) were 
significantly increased at higher PanK concentrations and these compounds 
were not subjected to NMR analysis. NMR binders ( ) - binding to PanK 
confirmed; NMR ambiguous ( ) - binding to enzyme could not be confirmed; 
Low solubility ( ) - compound not soluble enough for NMR analysis. 
Compound no. 42 ( ) is Acetyl CoA (a specific inhibitor of PanK). From top to 
bottom, the dotted lines represent 1, 2 and 3 SD’s respectively from the mean of 
the Acetyl CoA ratio.  
 
It has been previously established that testing enzyme concentration 
sensitivity was more predictive detergent sensitivity in identifying non-stoichiometric 
enzyme inhibitors from a PanK hit list without overly affecting stoichiometric 
enzyme inhibitors (Habig et al. 2009). All compounds represented in Figure 17 were 
chosen from the hit list mentioned above based on their sensitivity to enzyme 
concentration (see Materials and Methods). Among the 15 enzyme-concentration 
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sensitive (i.e. non-specific) PanK hits, 13 compounds had ratios much lower than 
3SD’s from the mean of the Acetyl CoA ratio, indicating aggregate formation in the 
assay buffer; and 2 compounds had ratios that fell in the borderline regions (Fig. 17). 
Among the 26 hits that were chosen for NMR analysis based on their enzyme-
concentration insensitive inhibition, 20 hits did not appear to form colloids as 
indicated by unaffected meniscus. Of the remaining 10, the 6 hits that had ratios 
lower than the cut-off were found to have solubility issues due to which they could 
not be characterized by NMR-based techniques; and the other 4 hits of which 3 were 













4.1 Choice of β-Lactamase as model enzyme 
 β-Lactamase was set-up as a model enzyme system to study aggregate-
forming inhibitors because it has been extensively studied. Since all mechanistic 
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studies by Shoichet et al. investigating the mode of action of aggregation-based 
inhibitors were performed with this model enzyme, inhibition of β-Lactamase by 
aggregate-forming inhibitors is well characterized. Large compound libraries have 
been tested to determine the feasibility of different methods of identifying aggregate-
forming inhibitors of β-Lactamase (McGovern et al. 2003; Feng et al. 2005; Feng et 
al. 2007). It has been well established that detergent-sensitive β-Lactamase inhibitors 
consistently display characteristic features of non-specific inhibition such non-
stoichiometric binding of the enzyme (verifiable by increasing the enzyme 
concentration by 10-fold) and form aggregate particles in solution (verifiable by DLS 
measurements of particle size). Results from numerous studies have validated 
detergent sensitivity as a convenient proxy for determination of aggregation-based 
inhibition. 
Furthermore, hits from a β-Lactamase screen were likely to be a good source 
of aggregate-forming inhibitors. Many drug like molecules from screening libraries 
have been observed to inhibit the enzyme (McGovern et al. 2002, McGovern and 
Shoichet 2003; Seidler et al. 2003). Further, a screen of 70,563 compounds against 
AmpC β-Lactamase highlighted aggregate forming compounds as the major source of 
false positives. Approximately 95% of the screening hits (1204 out of 1274) were 
reported to be colloidal aggregators (Feng et al. 2007). The utilization of a kinetic 
readout ensured that the interference from coloured substances on the assay readout 
was negligible. In addition, very few actives were found to be attributable to reactive 
compounds, with aggregators outnumbering the reactive hits by a ratio of over 100:1 
(Babaoglu et al. 2008).  These observations prompted the inference that non-specific 
covalent inhibition may be a minor issue where β-Lactamase is concerned and that 
the enzyme was possibly more vulnerable to inhibition by aggregate particles. Given 
the fact that β-Lactamase appears to have an increased susceptibility towards 
aggregate-based inhibition that is easily verifiable by the methods described above, 
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compounds that inhibit β-Lactamase would be ideal to substantiate whether or not an 
alternative technique for determination of compound aggregation has good predictive 
value. 
4.2 Design and implementation of compound library screening for inhibitors of 
β-Lactamase 
 
Shoichet’s group used E. Coli AmpC β-Lactamase in their assays, whereas 
Enterobacter Cloacae P-99 AmpC β-Lactamase was used for all experiments in this 
study due to its commercial availability. Though it has been established that E. 
cloacae β-Lactamase has a similar propensity to detergent-reversible inhibition by 
aggregate-forming compounds (Ryan et al. 2003); there have been no reports of large 
scale screens for inhibitors of this enzyme.  Before screening compounds against E. 
Cloacae P-99 β-Lactamase in this study, it was verified with known aggregators of E. 
Coli AmpC β-Lactamase (McGovern et al. 2002, McGovern et al. 2003) and specific 
inhibitors of the AmpC β-Lactamase family; that detergent sensitive inhibition of E. 
Cloacae P-99 β-Lactamase functioned in a manner similar to that of E. Coli β-
Lactamase (data not shown).   
A small compound library (Novartis2008), comprising approximately 8000 
compounds, was chosen to screen for inhibitors of E. Cloacae P-99 β-Lactamase. The 
primary screen was performed in detergent-free conditions utilizing a chromogenic 
assay format. One major deviation from the assay procedure followed by Shoichet et 
al. was the concentration of the chromogenic CENTA substrate.  Shoichet’s group 
used a high concentration of CENTA (Coan and Shoichet 2007) in their screens to 
avoid interference from coloured compounds; which was found to be at least 10 times 
higher than the reported Km (10µM) of this substrate (Bebrone et al. 2001). In this 
study, the primary screen was run at a final CENTA concentration of 25µM, which 
was five times lower than the concentration in previously reported screens and was 
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closer to the published Km of 10µM.  Since the enzyme has a tendency to stick to 
plastic surfaces as noted previously (Ryan et al. 2003), 25µM was also observed to be 
the minimum substrate concentration required to obtain a good signal window in 
detergent-free assay conditions. Running the primary screen in completely detergent-
free conditions did not influence screen quality; as the Z-factor associated with each 
plate remained above the required 0.5 cut-off (Fig. 5).  
A threshold of mean ± 3SD is often used to select hits if data is normally 
distributed. Since in this study, the distribution of compound activity was found to be 
skewed to the right (Fig. 6), hits with the highest percent inhibition were chosen 
instead.  A cut-off of 40.0% inhibition was selected based on normalized responses of 
all compounds in the library. Based on this cut-off, a hit rate of 0.23% was observed. 
This hit rate was found to be considerably lower than the 1.8% hit rate (1274 hits 
from a library of 70,563 compounds; Feng et al. 2007) obtained in a previous screen 
against E. Coli AmpC β-Lactamase. It is possible that the high substrate 
concentration (> 10-fold over Km) used in that screen biased the screen towards 
detection of non-competitive inhibitors and lead to an inflated hit rate.  
4.2.1 Prediction of aggregation-based inhibition by β-Lactamase hits based on 
sensitivity to detergent 
To address concerns that aggregate-based inhibition might be influenced by 
the nature of the detergent; due to detergent affecting either enzyme activity or 
interaction between enzyme and compound or both; sensitivity to three different 
detergents was tested.  One zwitterionic detergent (CHAPS) and two non-ionic 
detergents (Triton X-100 and Tween-20) were chosen.  The concentration used was 
kept well below the CMC of each detergent to prevent possible entrapment of the 
compound within detergent micelles.  The enzyme was found to have higher activity 
in the presence of detergent, possibly because addition of detergent to the buffer 
prevented the enzyme from binding to the assay plate (Ryan et al. 2003). The three 
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detergents impacted β-Lactamase activity differently. As observed from the controls 
on the assay plates, the enzyme was found to be most active in Tween-20 and Triton 
X-100 and least active in CHAPS.  None of the detergents appeared to affect the 
inhibitory potency of a specific, reversible inhibitor of β-Lactamase, BZBTH2B; as 
evidenced from the unchanged IC50’s in the detergent (+) screens (Table 2, Fig. 7). 
In the case of Tween-20, Triton X-100 or CHAPS addition to the assay 
buffer; 13 of the 14 hits displayed a dramatic decrease in potency (either complete 
loss of inhibition or more than a 3-fold increase in IC50). Only one compound, BLAC-
11, was found to inhibit β-Lactamase in the presence of detergent (Table 2, Fig. 8), 
suggesting that it did not inhibit via aggregate formation.  The results were consistent 
with the notion that a majority of β-Lactamase inhibitors act via an aggregation-based 
mechanism that can be detected by sensitivity of inhibition potency to detergent. The 
data suggested that although the various detergents influenced the enzymatic activity 
differently; attenuation of inhibition of β-Lactamase by aggregate-forming inhibitors 
was not found to depend on the type of detergent used in the counter screen. 
4.2.2 Prediction of aggregation-based inhibition by β-Lactamase hits based on 
sensitivity to enzyme concentration 
Testing the sensitivity of inhibition potency of the 14 hits to enzyme 
concentration was a challenging task. Ideally, the only variable in this counter screen 
should be concentration of the enzyme. However, upon increasing the enzyme 
concentration by 10-fold (2.5nM to 25nM) while keeping the concentration of the 
chromogenic substrate constant at 25µM; it was found that the substrate was depleted 
too quickly to allow measurement of reaction rate. The Shoichet laboratory uses a 
custom-made, slower-acting form of the chromogenic substrate at higher enzyme 
concentrations (McGovern et al. 2002).  In our laboratory, a commercially available 
slower-acting substrate, Penicillin G, failed to achieve a suitable signal window and 
gave an unacceptable Z’-factor  
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To enable measurement of change in potency of β-Lactamase inhibitors upon 
increasing enzyme concentration, a more sensitive assay format was sought.  
Fluorocillin green, a non-fluorescent substrate for β-Lactamase that yields a green 
fluorescent product on enzymatic or chemical hydrolysis of the lactam ring, has been 
used in recent years by research groups that work with E. Cloacae AmpC β-
Lactamase (Shukla and Krag 2009). In comparison to chromogenic substrates, it has 
been reported as a more sensitive means of assaying P99 β-Lactamase activity 
(personal communication, Shukla).  
  The fluorogenic assay format was found to have a broad, dynamic signal 
range. This facilitated measurement of enzyme activity at two enzyme concentrations 
10-fold apart while keeping the substrate concentration constant. The sensitivity of 
compound inhibition to enzyme concentration was tested in detergent-free conditions, 
in the same buffer that was used in the primary screen. Whereas with the 
chromogenic substrate, a minimum of 2.5nM of enzyme was required to observe a 
reaction signal, fluorocillin allowed quantification of enzyme activity with as low as 
0.5nM β-Lactamase. At this low concentration of 2.5nM, most hits had well defined 
dose-response curves with Hill co-efficients in the acceptable range (Table 3).  
To validate the applicability of this assay format in determining aggregate-
based inhibition, the detergent sensitivity counter screen was repeated with the 
fluorocillin substrate. The result was the same as that obtained in the determination of 
detergent sensitivity of hits using a chromogenic substrate; 13 of the 14 hits tested 
were found to display (Tables 2 and 3). The confirmation of detergent sensitivity by 
an orthogonal assay with a different readout established that neither method is biased 
towards detection of aggregate-forming inhibitors. 
4.2.3 Prediction of aggregation-based inhibition on the basis of particle size 
measurements of β-Lactamase hits using Dynamic Light Scattering 
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The particle sizes obtained by DLS were inconclusive in determining 
aggregation due to of the lack of reproducibility, sub-optimal data quality and high 
signal to noise ratios (Fig. 9, 10). The poor quality of data can be partly attributed to 
the inherently low resolution nature of DLS and its consequent inability in dealing 
with samples that have high degrees of polydispersity.  Recent studies have illustrated 
the limited ability of current DLS technology in providing reliable data on 
polydisperse samples (Filipe et al. 2010). These limitations have largely to do with 
the DLS particle-sizing models. The first order result from a DLS experiment is the 
intensity distribution of particle sizes. The DLS particle-sizing model assumes 
scattering from uniformly sized spherical particles. Drug-like compounds can 
aggregate in non-spherical forms (McGovern et al. 2002; Feng et al. 2008; Chan et al. 
2009, Doak et al. 2010). In addition, it is possible that aggregating compounds 
display size heterogeneity in solution and that the different aggregate species have 
irregular shapes (Fig. 2). These factors could lead to large fit errors (Malvern 
Instruments Technical Support, personal communication). The intensity distribution 
is weighted according to the scattering intensity of each particle fraction. Whereas 
particle-sizing models are capable of generating reliable particle size distributions for 
species with widely differing molecular masses, they are ill-equipped to resolve 
samples whose particle fractions don’t differ greatly in mass or size. Furthermore, the 
particle scattering intensity is proportional to the square of the molecular weight. As 
such, the intensity distribution can be somewhat misleading, in that larger particles 
can dominate the distribution.  
 The presence of unwanted signals in the scattered light is another major 
limitation to the quality of light scattering results. Studies have reported 
inconsistencies in particle size measurements due to elevated signal to noise ratios 
(Ryan et al. 2003; Chan et al. 2009). The occurrence of noise in DLS could be due to 
various factors such as fluctuations in the intensity of the laser beam, light scattering 
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by the solvent, convection currents in the scattering cell, scattering at the wrong 
angles due to reflections in the cell, or presence of foreign particles such as dust 
(Pecora 1985).  These factors can be a great hindrance in achieving reproducible 
measurements. 
Other factors such as optical and chemical properties of the test compound 
can influence the measurement. If a compound forms aggregates with dimensions 
comparable to the wavelength of light, intra-aggregate interference effects can 
dramatically reduce the apparent size of the aggregates (Bloomfield 2000). Further, 
compounds that absorb light at or near the wavelength used in the DLS measurement 
(between 500-650nm depending on instrument) may escape detection due to 
interference. For example, Congo red, a compound that is known to be an inhibitor of 
β-Lactamase and forms aggregates observable by TEM, does not form aggregates 
detectable by light scattering (McGovern et al. 2002; Feng et al. 2005).  
Signals from aggregates can be weak depending on the type of aggregate and 
the nature of the aggregating compound, leading to inconclusive results. A study on 
promiscuous inhibitors of β-Lactamase revealed that 27% of a set of randomly 
selected drug-like molecules were ‘ambiguous’ light scatterers and therefore could 
neither be classified as non-aggregators nor aggregators (Feng et al. 2005). The same 
study also noted discrepancies between DLS data and the tendency to inhibit enzyme 
activity via an aggregation-based mechanism. Some detergent-sensitive inhibitors did 
not scatter light by DLS and conversely all light-scattering compounds were not 
found to inhibit β-Lactamase. It was noted that light-scattering precipitates lacking 
inhibitory activity accounted for a significant proportion of the discrepancies, 
highlighting the inability of light scattering techniques to distinguish between 
precipitation and aggregation.  
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  For particle size measurements of β-Lactamase hits in this study, it 
was found that DLS analysis was a not suitable approach to get quantitative 
information about size of aggregate particles formed in solution.  The measurements 
were time-consuming; each compound often required repeated measurements due to 
lack of reproducibility. The measurement settings had to be adjusted for each 
compound; and despite efforts at optimization the raw data quality still remained sub-
standard. There are research groups that use DLS successfully to measure sizes of 
aggregates; therefore we can only speculate that either the hits from the β-Lactamase 
screen had qualities that interfered in the DLS measurements, or the equipment used 
was unsuitable for measurements of aggregates of drug like-molecules.  
4.3 Determination of specificity of DENV RdRp hits 
4.3.1 Assessment of classification of specificity of DENV RdRp hits based on 
detergent sensitivity of inhibition potency 
The hits from the pilot screen that passed both the auto-fluorescence and CIP 
inhibition counter screens (see Materials and Methods) were tested for sensitivity to 
detergent. The major difference compared to the β-Lactamase primary screen was 
that whereas β-Lactamase activity could be measured in the absence of detergent; 
some amount of detergent was needed to achieve a good signal window in the DENV 
RdRp assay. Therefore for the β-Lactamase detergent sensitivity counter screens, 
detergent was added to the buffer and the IC50’s in the presence and absence of 
detergent were compared; whereas for the DENV RdRp hits sensitivity to detergent 
was determined by testing the compounds at varying concentrations of detergent. 
To investigate whether the nature of detergent affected the inhibitory 
potencies of hits against DENV RdRp, the hits were re-tested for activity in the 
presence of Triton X-100, Brij-35 and CHAPS (Table 4). The IC50 values of the hits 
appeared to be highest in Brij-35, followed by Triton X-100 and then CHAPS; 
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however in many cases the IC50’s of the compound remained were not significantly 
changed. The fact that Brij-35 and Triton X-100 are non-ionic whereas CHAPS is 
zwitterionic might account for the difference in potencies in the presence of different 
types of detergent. The hits were subsequently tested at higher amounts of detergent, 
allowing quantification of change in IC50 as a measure of aggregate-based inhibition. 
The change in potency upon increasing detergent concentration was not consistent 
among the various detergents (Table 5). For many compounds, it was found that they 
displayed detergent-sensitive inhibition in only one of the detergents tested.  It is 
possible that each detergent interacts differently with the compound or the enzyme-
inhibitor complex.  
Detergent has been known to affect the interaction between enzymes and 
their inhibitors, depending on the type and the concentration used. In a study on West 
Nile virus protease, it has been observed that non-ionic detergents like Triton X-100 
and Tween-20 interfered with the inhibitory activity of a specific inhibitor of the 
protease at concentrations above 0.001%; whereas zwitterionic detergent CHAPS did 
not affect the inhibitory potency of the compound (Ezgimen et al. 2009). In another 
study, 0.05% Triton X-100 was found to disrupt the inhibition of the reverse 
transcriptase of human immunodeficiency virus type 1 by a specific inhibitor 
(Debyser et al. 1992). A study on Rce1p protease reported that disruption of 
aggregates was dependent on the concentration and type of detergent (Manandhar et 
al. 2007). It was found that aggregates of certain compounds were not dissociated by 
Triton X-100 below 0.04%; and that certain aggregates could be dissociated by Triton 
X-100 but not Tween-20 at a concentration near its CMC. This implies that specific 
inhibitors could be mis-identified as non-specific if detergent interferes in the 
interaction of the inhibitor with the enzyme. Thus determining specificity solely 
based on testing sensitivity of inhibition potency to detergent can be misleading. 
While in this study, the inhibition of DENV RdRp by its specific inhibitor, 3’dATP, 
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appeared to be unaffected by detergent type and concentration; this may not hold 
good for other specific inhibitors of the enzyme. Thus in a search for novel inhibitors 
of an enzyme such as DENV RdRp, it is necessary to be aware of fallible nature of 
detergent sensitivity in classifying whether or not a compound is a specific inhibitor. 
Another observation of interest was the frequency of detergent-sensitive 
inhibitors. Whereas for the non-ionic detergents Triton X-100 and Brij-35, of the 30 
hits, 43 and 54% respectively were detergent-sensitive inhibitors; only 20% of the 
hits had inhibition potency that was sensitive to zwitterionic CHAPS. Given that IC50 
values were lower in buffer containing a low concentration of CHAPS, IC50 shifts 
were conceivably less pronounced when compounds were subjected to a higher 
concentration of CHAPS; as opposed to shifts in Triton X-100 and Brij-35. 
Additionally, in comparison to previous reports on large numbers of detergent-
sensitive hits (as high as 95%) in screens against β-Lactamase (Feng et al. 2007) and 
cruzain (Jadhav et al. 2010), the number of hits that inhibited DENV RdRp in a 
detergent-sensitive manner was found to be much lower in all detergents tested. This 
could be because DENV RdRp is not as prone to sequestration by aggregating 
compounds as other enzymes. Since the binding between the DENV RdRp and its 
RNA substrate appears to be strong (~10nM Km
app for RNA substrate, Table 7); it is 
possible that the active enzyme which is in the form of an enzyme-RNA complex, is 
less susceptible to inhibition via an aggregation-based mechanism.  
 
4.3.2 Assessment of classification of specificity of DENV RdRp hits based on 
sensitivity of inhibition potency to enzyme concentration 
For inhibitors of DENV RdRp, testing sensitivity to enzyme concentration 
was complicated by the fact that it is a multi-substrate enzyme in which the substrates 
are charged. As mentioned earlier, the ideal scenario would be one where substrate 
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concentration was kept constant over the range of enzyme concentrations tested so 
that the only variable would be the amount of enzyme. Keeping the amount of the 
BBT-ATP substrate constant (at 2µM), inhibition was tested at 10nM and 100nM 
DENV RdRp. RNA concentrations of 50nM and 150nM were used for 10nM and 
100nM enzyme respectively to ensure that a saturated amount of RNA template was 
available to the enzyme for it to be able to initiate the reaction. Nine hits appeared to 
have inhibition that was insensitive to enzyme concentration (Table 6), but seven of 
these (RDRP- 1, 7, 13, 14, 15, 16, 26) were found to have attenuated inhibition in 
high amounts of at least one detergent (Table 5). Eight of the ten hits that had 
inhibition potencies insensitive to detergents appeared to lose potency at increased 
enzyme concentrations; indicating very poor agreement between these two methods 
of identifying non-specificity. 
   Besides the enzyme concentration, amount of 3’UTR-U30 RNA used in the 
reactions was the only other variable that might have influenced inhibition potency. 
Therefore effect of RNA concentration on DENV RdRp inhibition was examined 
(Fig. 11).  Compounds were re-tested at 10nM RdRp using an increased RNA 
concentration of 150nM, to match the substrate concentration used at 100nM enzyme. 
IC50 values were found to be lower than when 50nM RNA was used. In other words, 
the inhibitors appeared to be more potent when increased concentrations of RNA 
were used. Therefore, under the new conditions where RNA concentrations were now 
the same, 29 out of 30 hits had IC50’s that were more than 5-fold higher at 100nM 
compared to 10nM RdRp. An RNA concentration of 150nM was found to be more 
than 10-fold higher than the Km
app (~10nM) of the RNA substrate determined at 10nM 
DENV RdRp (Table 7). It was also observed that the rate of enzyme reaction began 
to drop at RNA concentrations above 50nM (Fig. 11). Thus it is possible that high 
concentrations of RNA had an adverse effect on the enzyme activity; causing the 
inhibitors to possibly appear more potent due to the enzyme being less active rather 
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than due to true inhibitory potency. Additionally, since RNA has a negative charge, it 
might bind to the enzyme non-productively (i.e. at non-catalytic sites) and lead to 
reduction in enzyme activity. Therefore changes in IC50 values at different enzyme 
concentrations could possibly be a DENV RdRp assay artifact caused due to 
interaction between the enzyme and substrate; rather than a reflection of non-specific 
inhibition. 
4.4 Steepness of dose-response curves as an indicator of aggregate-based 
inhibition 
 
Steep dose-response curves have been found to be associated with aggregate-
forming inhibitors of β-Lactamase (Feng et al. 2007). However, in this study, it was 
observed that the dose-response curves of the hits from the β-Lactamase screen were 
dependent on the assay format used to test the compounds. Of the 14 hits tested, it 
was observed that 13 hits had inhibition potencies that sensitive to detergent in both 
chromogenic and fluorometric assay formats. Whereas in the chromogenic format, 11 
compounds had steep dose-response curves with high Hill co-efficients, only 5 
compounds displayed steep dose-response curves in the fluorometric format (Tables 2 
and 3).  
There have been no reports on the nature of the dose-response curves of 
inhibitors of the DENV RdRp enzyme. A recent study on the association of dose-
response curves and inhibitory potential of anti-HIV drugs reported that different 
classes of anti-viral drugs were found to be typically associated with specific slope 
values (Shen et al. 2008). It was found that non-nucleoside and nucleoside inhibitors 
of the reverse transcriptase had dose-response curves associated with slopes values 
greater than 1 and ~1 respectively and that slopes were indicative of anti-viral activity 
of the compounds in vivo. 
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In this study, among the DENV RdRp hits, most compounds had slope values 
close to 1 (Table 4) and consequently the hits could not be separated into different 
slope classes. Furthermore, the steepness of dose-response curves of the RdRp hits 
found to be dependent on which detergent was added to the assay buffer (Table 5). 
None of the 30 hits had steep curves in buffer containing CHAPS, despite 10 hits 
displaying detergent sensitive inhibition at a higher concentration of CHAPS. Among 
the 16 hits that had lower inhibition potencies at a higher concentration of Triton X-
100, only 1 had a steep dose-response curve. Among the 13 hits that had higher IC50 
values at increased concentrations of Brij-35, only 5 hits had dose-response curves 
indicative of non-specific aggregation-based inhibition. Hence, slopes of the dose-
response curves were indicative of neither nature of inhibitor nor nature of inhibition 
among hits of the DENV RdRp enzyme.  
4.5 Target specificity of aggregate-forming inhibitors 
 
Many reports have claimed that inhibition of a panel of unrelated enzymes is 
a sign that that a compound is acting via an aggregation-based mechanism 
(McGovern et al. 2002; McGovern et al 2003). If aggregate-forming inhibitors were 
capable of inhibiting several targets by simply by virtue of sequestering/denaturing 
the enzyme, these compounds would frequently appear on hit lists from various 
screens. Since a majority of the hits from the β-Lactamase screen performed in this 
study were detergent-sensitive and therefore assumed to be aggregate-formers, these 
compounds should cause aggregation-based interference in other enzyme assays if 
non-specific aggregate-based inhibition was purely a characteristic of the respective 
compound. As can be seen in Figure 12, a retrospective analysis revealed that this 
does not appear to be the case. The compounds that inhibited β-Lactamase were not 
found to inhibit any other enzyme and vice versa. Since the inhibition of β-Lactamase 
by these hits was confirmed in a fluorometic assay format, it cannot be argued that a 
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particular assay format is predisposed to interference by aggregate-forming inhibitors. 
Extremely low frequency of overlap between the hits of two enzymes (Pantothenate 
Kinase and Nicotinamide adenine dinucleotide synthetase) for which exactly the 
same assay format was used further corroborates the dependence of aggregate-based 
assay interference target protein properties and assay conditions employed. 
 
The results of assaying hits from other enzyme assays for inhibition of β-
Lactamase, suggest that it cannot be used as a convenient proxy for aggregate-based 
promiscuity. If aggregation-based inhibition was dependent solely on the properties 
of the compound, we would expect more compounds that inhibited their target 
enzyme non-specifically to inhibit β-Lactamase; an enzyme known to be susceptible 
to aggregate-based inhibition (Ryan et al. 2003; McGovern et al 2003). However, 
only 10% of detergent-sensitive RdRp hits were found to inhibit the enzyme (Fig. 
13). In addition, compounds that specifically inhibit their respective target enzyme 
should not inhibit β-Lactamase enzyme as was found with some specific inhibitors of 
PanK (Fig. 14). As can be observed from hits of the RdRp and PanK enzyme, β-
Lactamase inhibition is not a good indicator of non-specificity. Thus inhibition of a 
model enzyme like β-Lactamase cannot be used as a generic assay to detect 
aggregation-based inhibition.  The results from this study further highlight the assay 
dependent and conditional nature of aggregate-based inhibition. 
 
4.6 Viability of change in meniscus assay as a generic assay for detection of 
aggregation 
 
The assay was initially validated using 14 known aggregators and 8 non-
aggregators (Cai and Gochin 2007). There have been no reports of its application in a 
HTS campaign.  As demonstrated in this study, measurement of change in meniscus 
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shape as an indicator of compound aggregation appears to have good predictive 
value. For the β-Lactamase hits, the classification of aggregate formers based on 
changes in meniscus was in good agreement with detection of aggregation-based 
inhibition based on detergent sensitivity tests (Fig. 15). For the DENV RdRp hits 
(Fig. 16), it is difficult to determine the predictive value of the meniscus 
measurements as for more than 50% of the hits; detergent sensitivity results were 
inconclusive due to lack of conformity between IC50 changes in different detergents 
(Table 5). Among the compounds for which sensitivity of compound inhibition to 
detergent was consistent in all 3 detergents tested, the meniscus data was generally 
found to be in agreement.  Among the PanK compounds, the assay accurately 
identified a majority of the enzyme-concentration sensitive (i.e. non-specific) 
inhibitors as aggregate formers. However, for the PanK hits that were designated as 
specific based on insensitivity of compound inhibition to enzyme concentration; there 
were a few compounds that had ratios normally associated with colloid formation 
(Fig. 17). Additionally, the specific compounds among the PanK hits with ratios 
much smaller than 3SD’s from the mean of the reference inhibitor (Acetyl CoA) ratio 
could not be confirmed as binders by NMR analysis due to poor solubility. Thus 
either they were false positives in the enzyme-concentration sensitivity tests or false 
negatives in the assay measuring changes in meniscus.  
As with any other assay, there is the possibility that the meniscus assay can 
incorrectly classify compounds. Interaction of compounds with the fluorescent dye 
included in the buffer can influence the fluorescence intensity without a 
corresponding change in liquid meniscus (Cai and Gochin 2007). Cloudy aggregate 
solutions or coloured compounds that strongly absorb light and affect the readout are 
other sources of assay interference (personal communication, Cai). Formation of 
aggregate particles by a compound does not always translate to enzyme inhibition 
(Feng et al. 2005). Therefore even if a compound was found to bring about a change 
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in the shape of the liquid meniscus due to colloid formation, it may not necessarily be 
found to inhibit the target in an assay measuring enzyme activity. Furthermore, there 
is a caveat to detection of aggregation by a compound in the absence of enzyme. 
Some compounds only form aggregates in the presence of enzyme (Reddie et al. 
2006) and therefore would escape detection by in the meniscus assay but can be 
detected in an assay involving measurement of enzyme activity.  
As demonstrated in this study, an assay measuring changes in meniscus shape 
can be applied to study inhibitors of any enzyme. Since the change in meniscus shape 
due to formation colloidal particles is based on pronounced capillarity observable in 
high density (384, 1536) multi-well plates, the assay is utilizable in high throughput 
settings. As opposed to testing sensitivity of compound inhibition to detergent or 
enzyme concentration, the assay directly detects aggregate formation by the 
compound and does not involve either enzyme or substrate. Thus no knowledge of 
enzyme kinetics or interaction of detergent with the target enzyme is required. The 
assay is not limited by choice of buffer and allows measurement of compound 
aggregation in the buffer used to measure enzyme activity. As aggregation of small 
molecule compounds is partially dependent on the composition of the aqueous 
medium (Augustijns and Brewster 2007), detecting aggregate formation in the assay 
buffer is more relevant than testing whether or not a compound inhibits a model 
enzyme like β-Lactamase. While this assay involves use of detergents such as Triton 
X-100 and Tween-20, the purpose of the detergents is not to prevent aggregation or 
prevent interaction of the target enzyme with aggregate particles. Rather, it exploits 
the ability of detergent micelles to induce a change in the shape of the liquid 
meniscus, allowing assay buffer containing detergent at concentrations higher than its 
CMC to serve as a control.  A ratio of observed fluorescence of compound in assay 
buffer to that of compound in the same assay buffer containing detergent thus ensures 




4.7 Concluding remarks  
 
 As seen from the lack of correlation between hits from screens of different 
enzymes, aggregate-forming inhibitors appear to be target specific rather than 
‘promiscuous’. The ability of a compound to inhibit a target via an aggregation-based 
mechanism appears to depend on factors such as nature of the target enzyme, enzyme 
kinetics, assay conditions employed to measure enzyme activity and the nature of the 
compound itself. A compound that inhibits its target enzyme specifically could 
potentially inhibit another enzyme non-specifically. The results advise against a one-
off characterization of library compounds and suggest that identification of 
aggregation-based inhibition needs to be addressed for each new target separately. 
 Additionally, as seen from this study, testing sensitivity of compound 
inhibition to enzyme concentrations requires a good understanding of the enzyme 
kinetics and measurement of change in inhibition potencies in the presence of 
detergent can be influenced by the type of detergent used. To avoid falsely labelling 
compound inhibition as detergent-sensitive as a result of interaction between the 
detergent and enzyme or enzyme/inhibitor complex; ideally the effects of more than 
one detergent should be tested. Hence, measuring changes in inhibition potency at 
varying detergent or enzyme concentrations can be a tedious process. 
 The meniscus-based aggregation assay, on the other hand, is simple to 
implement and provides a quantitative direct measurement of formation of aggregates 
in solution. The assay is practicable in high throughput settings without the 
requirement of specialized equipment or time-consuming data-analysis. In future 
studies, the concentration dependence of aggregation could easily be followed using a 
dose-response curve in the fluorescence assay. In addition, formation of aggregate 
particles could be monitored in the presence of the target enzyme or active form of 
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the enzyme in the form of a complex (e.g., active form of DENV RdRp is in the form 
of DENV RdRp-RNA complex). Since this assay directly measures aggregate 
formation rather than enzyme activity, no knowledge of enzyme kinetics would be 
required. Furthermore, the assay would require no additional optimization, merely an 
additional step of inclusion of enzyme in the assay buffer. 
Therefore, using meniscus measurements as an indication of aggregate 
formation; large numbers of HTS hits could conceivably be prioritized efficiently for 
subsequent characterization by methods such as isothermal calorimetry, NMR, 
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